document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule item summary signature right trademark copyright trade name business include follow gilead gilead science ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvada prep tybost vemlidy viread vosevi yescarta zydelig lexiscan register trademark astella llc macugen register trademark bausch health ireland limited symtuza register trademark janssen sciences ireland uc tamiflu register trademark hoffmannla roche inc report refer trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue forecast variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forwardlooke statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forward look statement reason include identify item annual report head risk factor give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption item business gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include viral disease inflammatory fibrotic disease oncology seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategic collaboration principal product innovative medicine represent advancement offering enhance mode delivery convenient treatment regimen improve resistance profile reduce effect great efficacy focus innovation allow deliver market product multiple therapeutic area principal product approve indication united states follow hivaids biktarvy oral formulation dose day treatment hiv infection certain patient biktarvy single tablet regimen fixeddose combination antiretroviral medication bictegravir emtricitabine tenofovir alafenamide taf descovy oral formulation indicate combination antiretroviral agent treatment hiv infection certain patient descovy fixeddose combination antiretroviral medication emtricitabine taf descovy approve food drug administration fda preexposure prophylaxis prep indication reduce risk sexually acquire hiv infection certain atrisk patient odefsey oral formulation dose day treatment hiv infection certain patient odefsey single tablet regimen fixeddose combination antiretroviral medication emtricitabine taf rilpivirine market janssen sciences ireland uc janssen pharmaceutical companies johnson johnson janssen genvoya oral formulation dose day treatment hiv infection certain patient genvoya single tablet regimen fixeddose combination antiretroviral medicine elvitegravir cobicistat emtricitabine taf stribild oral formulation dose day treatment hiv infection certain patient stribild single tablet regimen fixeddose combination antiretroviral medication elvitegravir cobicistat tenofovir disoproxil fumarate tdf emtricitabine compleraeviplera oral formulation dose day treatment hiv infection certain patient product market united states complera europe eviplera single tablet regimen fixeddose combination antiretroviral medication tdf emtricitabine janssen rilpivirine hydrochloride atripla oral formulation indicate complete regimen treatment hiv infection certain patient atripla fixeddose combination antiretroviral medication tdf emtricitabine bristolmyers squibb company bmss efavirenz truvada oral formulation indicate combination antiretroviral agent treatment hiv infection certain patient fix dose combination antiretroviral medication tdf emtricitabine truvada approve fda prep indication combination safe sex practice reduce risk sexually acquire hiv infection certain atrisk patient liver disease vosevi oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir voxilaprevir retreatment chronic hepatitis c virus hcv infection adult genotype previously treat nsa inhibitorcontaine regimen ii genotype previously treat sofosbuvircontaine regimen nsa inhibitor epclusa oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir treatment chronic hcv infection adult genotype cirrhosis compensate cirrhosis ii decompensate cirrhosis use combination ribavirin harvoni oral formulation oncedaily single tablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adult genotype cirrhosis compensate cirrhosis ii adult genotype infection decompensate cirrhosis combination ribavirin iii adult genotype liver transplant recipient cirrhosis compensate cirrhosis combination ribavirin iv certain pediatric patient genotype cirrhosis compensate cirrhosis vemlidy oral formulation taf dose day treatment chronic hepatitis b virus hbv infection adult compensate liver disease viread oral formulation tdf dose day treatment chronic hbv infection adult certain pediatric patient hematologyoncology yescarta axicabtagene ciloleucel chimeric antigen receptor car cell therapy treatment adult patient relapse refractory large b cell lymphoma line systemic therapy include diffuse large bcell lymphoma dlbcl specify primary mediastinal large bcell lymphoma highgrade bcell lymphoma dlbcl arise follicular lymphoma zydelig idelalisib oral formulation kinase inhibitor treatment patient relapse chronic lymphocytic leukemia cll combination rituximab rituximab consider appropriate therapy comorbidities ii relapse follicular bcell non hodgkin lymphoma fl patient receive prior systemic therapy iii relapse small lymphocytic lymphoma receive prior systemic therapy letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsen ii combination tadalafil reduce risk disease progression hospitalization worsen pah improve exercise ability ranexa ranolazine oral formulation extendedrelease tablet antianginal treatment chronic angina ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment invasive fungal infection cause fungal specie adult information product revenue include revenue contribute product list fiscal year note revenue note consolidated financial statement include ii item annual report commercialization distribution international commercial sale operation marketing subsidiary country product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute product united states exclusively wholesale channel product sale large wholesaler amerisourcebergen corporation cardinal health inc mckesson corporation account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total worldwide revenue sell distribute product europe country outside united states product approve commercial team thirdparty distributor corporate partner competition operate highly competitive environment face significant competition global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete commercially available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing product mature private insurer government payer reduce reimburse patient increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect description competitor item risk factor face significant competition research development research development rd philosophy strategy develop bestinclass drug improve safety efficacy unmet medical need intend continue commit significant resource internal rd opportunity external business development activity product development effort focus primarily viral disease inflammatory fibrotic disease oncology research scientist engage discovery development new molecule technology hope lead approval new medicine advance current standard care address unmet medical need development product candidate subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate successfully commercialize drug development inherently risky product candidate fail drug development process continue invest advance rd pipeline therapeutic area end rd pipeline include active clinical study phase clinical trial summary key product candidate correspond current stage development product candidate viral disease product candidate description phase gs gs capsid inhibitor evaluate treatment hiv infection selgantolimod selgantolimod tlr agonist evaluate treatment chronic hbv infection phase vesatolimod vesatolimod tlr agonist evaluate potential cure hiv infection elipovimab elipovimab broadly neutralize antibody evaluate potential cure hiv infection gs gs pdl inhibitor evaluate treatment chronic hbv infection product candidate inflammatory fibrotic disease product candidate description phase filgotinib filgotinib jak inhibitor evaluate treatment crohns disease ii ulcerative colitis iii psoriatic arthritis cilofexor cilofexor fxr agonist evaluate treatment primary sclerose cholangitis glpg glpg autotaxin inhibitor evaluate treatment idiopathic pulmonary fibrosis phase filgotinib filgotinib evaluate treatment ankylose spondylitis ii uveitis gs gs tpl inhibitor evaluate treatment ulcerative colitis glpg glpg adamts inhibitor evaluate treatment osteoarthritis selonsertib selonsertib ask inhibitor evaluate treatment diabetic kidney disease cilofexor firsocostat selonsertib combinations cilofexor firsocostat acc inhibitor selonsertib combination evaluate treatment nonalcoholic steatohepatitis nash glpg glpg evaluate treatment systemic sclerosis glpg glpg gpr inhibitor evaluate treatment idiopathic pulmonary fibrosis phase glpg glpg evaluate treatment inflammatory disease glpg glpg evaluate treatment inflammatory disease glpg glpg evaluate treatment inflammatory disease glpg glpg evaluate treatment inflammatory disease product candidate oncology product candidate description phase axicabtagene ciloleucel axicabtagene ciloleucel evaluate treatment second line dlbcl phase axicabtagene ciloleucel axicabtagene ciloleucel evaluate treatment indolent nonhodgkin lymphoma axicabtagene ciloleucel evaluate treatment line dlbcl ii dlbcl combination rituximab lenalidomide ktex ktex car cell therapy evaluate treatment adult pediatric acute lymphoblastic leukemia ii cll phase axicabtagene ciloleucel axicabtagene ciloleucel evaluate treatment dlbcl combination utomilumab kite kite mage aa evaluate treatment solid tumor kite kite hpv e evaluate treatment solid tumor gs gs bispecific antibody evaluate treatment solid tumor gs gs oral pdl inhibitor evaluate treatment solid tumor agen agen bispecific mab evaluate treatment multiple indication oncology agen agen anticd mab evaluate treatment multiple indication oncology optionable partner program optione partner program addition internal discovery clinical development program seek add portfolio product product acquisition inlicense strategic collaboration complete strategic partnership license deal equity investment reflect commitment develop pipeline range disease address area significant unmet medical need position longterm growth business patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent phase product candidate product candidate fixeddose combination single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen phase product candidate patent expiration eu product candidate inflammatory fibrotic disease filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis psoriatic arthritis glpg treatment idiopathic pulmonary fibrosis cilofexor treatment primary sclerose cholangitis product candidate oncology axicabtagene ciloleucel treatment second line dlbcl composition matter patent expire european union european union united states patent application pende relate proprietary manufacturing process kite gilead company follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent principal product product fixeddose combination single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen product patent expiration eu letairis ranexa atripla truvada descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant gilead watson laboratories inc reach agreement settle patent litigation matter relate letairis gilead lupin limit reach agreement settle patent litigation matter relate ranexa gilead teva pharmaceuticals reach agreement settle patent litigation concern patent protect emtricitabine truvada atripla product additional information item risk factor face significant competition supplementary protection certificate spc grant european country validity spc challenge generic manufacturer launch compete product application patent term extension file united states grant extend expiration date application patent term extension pende united states andor spc pende country european union product composition matter patent expire european union european union united states patent application pende relate proprietary manufacturing process kite patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent cover certain active pharmaceutical ingredient api hiv product yescarta hold party acquire exclusive right patent agreement party obtain patent certain product year marketing approval obtain patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent party infringe valid patent party reputation harm require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel bictegravir patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation proceeding enforcement validity exist patent future patent result invalidation patent substantially reduce protection time time certain individual entity challenge patent pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country provide effective enforcement patent thirdparty manufacturer able sell generic version product country description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include ii item annual report trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect manufacture raw material product manufacture facility thirdparty contract manufacturer depend party perform manufacturing activity majority api drug product product include hiv hcv product use multiple thirdparty contract manufacturer primary backup supplier manufacturing site yescarta establish clinical commercial manufacturing facility cell processing activity future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale manufacturing facility lease manufacturing facility manufacture distribute certain product api clinical andor commercial use facility locate foster city san dimas la verne oceanside el segundo california dublin cork ireland hoofddorp netherlands edmonton canada foster city california conduct process chemistry research formulation development activity manufacture api drug product clinical trial oversee thirdparty contract manufacturer san dimas la verne california manufacture ambisome package label majority commercial product distribution america pacific rim oceanside california utilize facility clinical manufacturing process development biologic candidates el segundo california utilize facility clinical commercial manufacturing processing yescarta cork dublin ireland utilize cork facility commercial manufacturing packaging labeling product perform quality control testing labeling package final release product distribution european union international market dublin facility responsible distribution activity product edmonton canada conduct process chemistry research scaleup activity clinical development candidate manufacture api investigational commercial product conduct chemical development activity improve exist commercial manufacturing process hoofddorp netherland utilize facility commercial manufacturing processing yescarta thirdparty manufacturer believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict reveal technology certain thirdparty manufacturer comply restriction information thirdparty manufacturer item risk factor manufacture problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda european medicine agency similar regulation effect jurisdiction manufacture operation subject routine inspection regulatory agency yescarta require fda comply risk evaluation mitigation strategy program include educate certify medical personnel therapy procedure potential effect profile therapy potential adverse effect relate cytokine release syndrome neurologic toxicity additionally require maintain complex chain identity custody respect patient material material move manufacturing facility manufacturing process patient access raw material need access certain raw material conduct clinical trial manufacture product raw material generally available multiple source purchase worldwide normally available quantity adequate meet need business attempt manage risk associate supply chain inventory management relationship management evaluation alternative source feasible information item risk factor able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue seasonality operation backlog worldwide product sale reflect significant degree seasonality endus demand united states fluctuation wholesaler inventory level impact product sale observe strong wholesaler subwholesaler purchase product fourth quarter result inventory drawdown wholesaler subwholesaler subsequent quarter factor include government budget annual grant cycle federal state fund buy pattern impact product sale record particular quarter information item risk factor inability accurately predict demand product fluctuation purchase pattern wholesaler inventory make difficult accurately forecast sale cause forecast revenue earning fluctuate adversely affect financial result stock price operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states european union country include law regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume regulatory requirement applicable drug development approval subject change legal regulatory change impact operation future country regulatory agency fda united states european commission european union national authority european union member state approve drug sell respective country country general process drug approval united states summarize country include country european union similar regulatory structure preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum clinical trial acceptable benefitrisk profile submit appropriate filing usually form new drug application nda supplemental nda fda seek approval sell drug candidate particular use fdas discretion fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard concern safety efficacy uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california license state california compliance local regulatory requirement manufacture facilities canada ireland netherlands obtain local license permit compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite review european union regulatory system approval process european union eu products subject variety eu eu member state regulation govern clinical trial commercial sale distribution require obtain marketing authorization eu market medicinal product relevant market conduct clinical trial eu govern directive ec eu good clinical practice rule impose legal regulatory obligation similar provide applicable law conduct clinical trial eu approve competent authority eu member states clinical trial place positive opinion obtain relevant ethic committee relevant member state eu legislator adopt regulation eu replace directive ec introduce coordinated procedure authorization clinical trial regulation expect apply marketing authorization holder manufacturer importer wholesaler distributor medicinal product place market eu require comply number regulatory requirement include pharmacovigilance good manufacturing practice compliance requirement obtain manufacture import andor distribution license issue competent authority eu member states failure comply requirement lead imposition civil criminal administrative sanction include suspension marketing manufacturing authorization pricing reimbursement successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service significant portion sale majority product subject substantial discount list price result price increase implement time time certain product limit effect product sale certain market addition standard reimbursement structure adequately reimburse innovative therapy product mature private insurer government payer reduce reimburse provider increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect information item risk factor exist product subject reimbursement government agency party require provide rebate discount product result adjustment product revenue pharmaceutical pricing reimbursement pressure adversely affect profitability result operation inability accurately predict demand product fluctuation purchase pattern wholesaler inventory make difficult accurately forecast sale cause forecast revenue earning fluctuate adversely affect financial result stock price patient assistance program recently enhance scrutiny companysponsore patient assistance program include copay assistance program manufacturer donation thirdparty charity provide assistance enhance scrutiny government reimbursement support offering clinical education program promotional speaker program agent vendor deem fail comply law regulation government guidance area subject criminal civil sanction similar violation competitor negatively impact industry reputation increase scrutiny business product health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law anti kickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim sale marketing patient support medical activity subject scrutiny law similarly europe interaction pharmaceutical company physician subject strict law regulation industry selfregulation code conduct physician code professional conduct applicable include eu member states anti corruption law uk bribery act addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect reckless criminal act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program healthcare reform federal state government continue propose pass legislation design regulate healthcare industry include legislation seeks indirectly directly regulate pharmaceutical drug pricing information item risk factor result operation adversely affect current potential future healthcare legislative regulatory action law regulation applicable health care industry impose new obligation require change business practice restrict operation future employee january approximately employee believe good relation employee environment subject number law regulation require compliance federal state local regulation protection environment regulatory landscape continue evolve anticipate additional regulation future law regulation implement consideration mitigate effect climate change mainly cause greenhouse gas emission business energy intensive anticipate subject cap trade system mitigation measure materially impact capital expenditure operation competitive position information subject information requirement securities exchange act exchange act file periodic report proxy information statement information sec sec maintains website httpwwwsecgov contain report proxy information statement information issuer file electronically sec mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors website sec filing section available follow filing free charge soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale hiv product unable increase maintain hiv sale result operation adversely affect receive substantial portion revenue sale product treatment prevention hiv infection year end december sale hiv product account approximately total product sale hiv product account high percentage total product sale hiv product contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf andor emtricitabine ftc belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebase therapeutic fall favor unable maintain increase hiv product sale result operation likely suffer likely need scale operation include future drug development spending research development rd effort addition future sale hiv product depend extent reimbursement product private public payer continue experience global pricing pressure result large discount rebate product delay reimbursement negatively impact product sale result operation private public payer choose exclude product formulary coverage list limit type patient coverage provide negatively impact demand revenue product change formulary coverage reimbursement level discount rebate offer product payer impact anticipate revenue unable achieve forecast hiv sale stock price adversely impact unable sustain increase sale hiv product number reason include limited reason discuss follow product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue product mature private insurer government payer reduce reimburse patient product increase pressure reduce price physician benefit hiv product sale hiv product limit new branded generic product introduce major market ability maintain pricing market share affect fail develop commercialize new product expand indication exist product prospect future revenue result operation adversely affect success business depend ability introduce new product expand indication exist product address area unmet medical need launch commercially successful product necessary cover substantial rd expense offset revenue loss exist product lose market share factor competition loss patent exclusivity provide growth business difficulty uncertaintie inherent drug development introduction new product product development cycle characterize significant investment resource long lead time unpredictable outcome nature develop medicine human use expend significant time resource product pipeline assurance recoup investment effort commercially successful high rate failure inherent discovery development new product failure occur point process include late process substantial investment example face risk clinical trial include potential unfavorable result delay anticipate timeline disruption adversely affect prospect future revenue growth result operation state certainty product candidate development approve launch able develop license acquire additional product candidate product product launch commercially successful failure launch commercially successful new product new indication exist product material adverse effect future revenue result operation longterm success inability accurately predict demand product fluctuation purchase pattern wholesaler inventory make difficult accurately forecast sale cause forecast revenue earning fluctuate adversely affect financial result stock price unable accurately predict demand product include uptake new product demand depend number factor example nonretail sector united states include government institution include state aids drug assistance program adap department veteran affair correctional facility large health maintenance organization tend consistent term buy pattern cause quarteroverquarter fluctuation necessarily mirror patient demand product federal state budget pressure annual grant cycle federal state fund cause purchasing pattern reflect patient demand product expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future sell distribute product united states exclusively wholesale channel year end december approximately product sale united states wholesaler amerisourcebergen corporation cardinal health inc mckesson corporation wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesaler location inventory management agreement control buy pattern adverse change economic condition increase competition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesaler order end user demand change addition observe strong wholesaler subwholesaler purchase product fourth quarter typically result inventory drawdown wholesaler subwholesaler subsequent quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue face significant competition face significant competition global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing tafcontaine hiv product compete primarily product viiv healthcare company viiv face competition generic hiv product generic version efavirenz component atripla available united states canada europe observe pricing pressure relate efavirenz component atripla sale tdf active pharmaceutical ingredient truvada atripla compleraeviplera stribild face generic competition european union united states certain country addition ftc active pharmaceutical ingredient truvada face generic competition european union truvada face generic competition european union certain country outside united states pursuant settlement agreement relate patent protect truvada atripla teva pharmaceuticals permit launch generic fixeddose combination ftc tdf generic fixeddose combination ftc tdf efavirenz united states september hepatitis c virus hcv product compete primarily product market abbvie inc merck co inc hepatitis b virus hbv product face competition exist therapy treat patient hbv generic version tdf hbv product compete product market bristolmyer squibb company novartis pharmaceutical corporation novartis yescarta compete car cell therapy market novartis noncar product market roche expect compete product company develop advanced cell therapy yescarta commercial product face competition certain clinical trial enrol car eligible patient addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share result new technology commercialization strategy adversely affect result operation stock price require pay significant damage royalty payment result ongoing litigation relate yescarta biktarvy adverse outcome ongoing litigation relate yescarta biktarvy product require pay significant monetary damage royalty payment past future sale predict ultimate outcome litigation matter time magnitude payment material adverse impact result operation financial condition stock price october juno therapeutics inc sloan kettere cancer center collectively juno file lawsuit district court central district california allege commercialization axicabtagene ciloleucel sell commercially yescarta infringe patent patent jury trial hold patent december jury find asserted claim patent valid willfully infringe assert claim patent jury award juno damage amount million upfront payment run royalty october date jurys verdict party file posttrial motion january file briefing quarter expect judge rule matter later district court issue ruling enter judgment case appeal court appeal federal circuit predict certainty ultimate outcome litigation believe jurys verdict error believe error court respect certain ruling trial jurys verdict upheld appeal loss zero jurys verdict upheld entirety appeal estimate upper end range possible loss december approximately billion consist million upfront payment determined jury ii approximately million represent estimate royalty adjust revenue yescarta october december iii enhance damage request juno time sum ii result jurys find willfulness sum exclude cost pre judgment interest supplemental damage consist royalty sale yescarta december date judgment subject royalty jurys verdict prospective royalty propose juno enhancement postjudgment sale yescarta subject prospective royalty estimate payable adjusted yescarta revenue judgment expiry patent august expect judge rule prospective royalty enhance damage course decide posttrial motion court determination prospective royalty enhance damage appeal jurys verdict upheld appeal require pay juno significant payment material adverse impact result operation financial condition stock price february viiv file lawsuit district court delaware allege commercialization bictegravir sell commercially combination taf ftc biktarvy infringe viiv patent patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claim patent extent viivs patent claim interpret cover bictegravir believe claims invalid court set trial date september lawsuit information litigation relate litigation country outside united states note commitment contingency note consolidated financial statement include ii item annual report predict certainty ultimate outcome litigation adverse judgment result significant monetary damage royalty payment past future sale material impact result operation financial condition stock price result operation adversely affect current potential future healthcare legislative regulatory action legislative regulatory action affect government prescription drug procurement reimbursement program occur relatively frequently united states affordable care act aca enact expand healthcare coverage numerous effort repeal amend administratively limit aca example december court appeal fifth circuit hold individual health insurance mandate aca unconstitutional remand case district court determine provision aca stand individual health insurance mandate ongoing challenge aca new legislative proposal result uncertainty acas future viability destabilization health insurance market result impact business uncertain material effort control prescription drug price material adverse effect business example president trump secretary department health human service hhs release american patient blueprint begin implement certain portion initiative include proposal increase generic drug biosimilar competition enable medicare program negotiate drug price directly improve transparency drug price low consumer outofpocket cost trump administration propose establish international pricing index benchmark determine cost potentially limit reimbursement drug medicare b addition december food drug administration fda issue proposal implement pathway legal importation certain prescription drug canada prescription drug fdaapprove manufacture abroad authorize sale foreign country originally intend sale foreign country pharmaceutical manufacturer industryrelate proposal congress propose bill change medicare benefit impose inflationbase rebate medicare alter benefit structure increase manufacturer contribution benefit phase volume drug pricingrelate bill dramatically increase current congress result impact business uncertain material addition majority state enact legislation seeks indirectly directly regulate pharmaceutical drug pricing require biopharmaceutical manufacturer publicly report proprietary pricing information create review board recommend price cap mean control price pharmaceutical product purchase state agency example california governor sign prescription drug price transparency state bill law require prescription drug manufacturer provide advance notice explanation price increase certain drug exceed specify threshold state propose enact similar legislation addition state legislature consider pass bill reform drug purchasing price negotiation facilitate import lowerprice drug outside united states encourage use generic drug initiative legislation cause add pricing pressure product change medicaid program federal state level material adverse effect business proposal impact coverage reimbursement product include give state flexibility manage drug cover medicaid program material adverse effect limit product use coverage furthermore state medicaid program request additional supplemental rebate product reason extent private insurer manage care program follow medicaid coverage payment development use enactment increase rebate exert pricing pressure product adverse effect magnify adoption low payment schedule propose regulatory action affect manufacturer material adverse effect business difficult predict impact propose legislative regulatory action result state action use reimbursement product united states action adversely affect result operation country outside united states include european union eu member states establish complex lengthy procedure obtain price approval coverage reimbursement eu member states review periodically decision concern pricing reimbursement medicinal product outcome review predict adverse effect pricing reimbursement medicinal product eu member states reduction price medicinal product eu member state affect price eu member state negative impact financial result exist product subject reimbursement government agency party require provide rebate discount product result adjustment product revenue pharmaceutical pricing reimbursement pressure adversely affect profitability result operation successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service substantial portion product sale subject significant discount list price include rebate required pay certain governmental agency addition standard reimbursement structure adequately reimburse innovative therapy example fiscal year center medicare medicaid services cms establish medicare inpatient reimbursement yescarta include payment severity adjust diagnosis relate group drg new technology addon payment ntap yescarta cover cost yescarta cover case outli payment take total payment sufficient reimburse hospital cost care patient receive yescarta cms decision pay yescarta fiscal year medicare adequately reimburse cost yescarta impact willingness hospital offer therapy doctor recommend therapy lessen attractiveness therapy patient adverse effect sale yescarta result operation additionally european union barrier reimbursement individual country limit uptake yescarta addition estimate rebate require pay connection sale particular quarter base claim datum prior quarter united states actual rebate claim typically payer quarter arrear actual claim payment vary significantly estimate cause adjustment product revenue extent actual anticipate product revenue fall short investor expectation stock price adversely impact information concern eu pricing reimbursement regime result operation adversely affect current potential future healthcare legislative regulatory action law regulation applicable health care industry impose new obligation require change business practice restrict operation future health care industry subject federal state international law regulation pertain drug reimbursement rebate price report health care fraud abuse datum privacy security united states law include antikickback false claim law law regulation relate medicare medicaid programs federal state program medicaid rebate statute individual state law relate pricing sale marketing practice health insurance portability accountability act hipaa federal state law relate privacy security health information violation law relate regulation punishable criminal andor civil sanction include instance substantial fine civil monetary penalty exclusion participation federal state health care program include medicare medicaid veterans administration health program federal employee health benefit program action executive oversee business significant remediation measure addition law regulation broad scope subject change evolving interpretation require incur substantial cost associate compliance alter sale marketing practice violation law allegation violation result negative publicity consequence harm reputation disrupt business adversely affect result operation event occur business stock price materially adversely affect recently enhance scrutiny companysponsore patient assistance program include copay assistance program manufacturer donation thirdparty charity provide assistance enhance scrutiny government reimbursement support offering clinical education program promotional speaker program agent vendor deem fail comply law regulation government guidance area subject criminal civil sanction similar violation competitor negatively impact industry reputation increase scrutiny business product addition government price report payment regulation complex continually assess method calculate report pricing accordance obligation methodology calculation inherently subjective subject review challenge government agency disagree interpretation government disagree report calculation need restate previously report datum subject additional financial legal liability describe description government investigation relate litigation note commitment contingency note consolidated financial statement include ii item annual report yescarta chimeric antigen receptor car cell therapy represent novel approach cancer treatment create significant challenge impact ability increase sale yescarta yescarta car cell therapy involve harvesting cell patient blood ii engineering cell express cancerspecific receptor iii increase number engineer cell iv infuse functional cancerspecific cell patient advance novel personalize therapy create significant challenge include educate certify medical personnel procedure potential effect profile therapy potential adverse effect relate cytokine release syndrome neurologic toxicity compliance risk evaluation mitigation strategy program require fda yescarta medicine manage adverse effect therapy tocilizumab corticosteroid available sufficient quantity adequately control effect andor detrimental impact efficacy treatment develop robust reliable process limit contamination risk engineering patient cell ex vivo infuse engineer cell patient conditioning patient chemotherapy advance administer therapy increase risk adverse effect use engineer cell potential cancer treatment recent development broadly accept physician patient hospital cancer treatment center payer medical community able establish demonstrate medical community commercial governmental payer safety efficacy yescarta potential advantage compare exist future therapeutic challenge relate reimbursement yescarta exist product subject reimbursement government agency party require provide rebate discount product result adjustment product revenue pharmaceutical pricing reimbursement pressure adversely affect profitability result operation fail overcome significant challenge sale yescarta result operation stock price adversely affect engaged future engage business acquisition licensing arrangement collaboration disposal asset strategic transaction cause incur significant expense adversely affect financial condition result operation engage future engage business acquisition licensing arrangement collaboration disposal asset transaction business strategy identify suitable transaction future complete transaction timely manner costeffective basis realize expect benefit example successful make acquisition product technology acquire successful require significantly great resource investment originally anticipate able integrate acquisition successfully exist business incur assume significant debt unknown contingent liability acquire future acquire equity investment strategic transaction connection collaboration galapagos nv value equity investment fluctuate decline value conduct annual impairment testing goodwill indefinitelive intangible asset fourth quarter early impairment indicator exist require generally accept accounting principle result impairment charge example fourth quarter recognize million million respectively impairment charge related indefinitelive intangible asset acquire connection acquisition kite pharma inc fail overcome risk cause incur significant expense negatively affect profitability adverse effect result operation experience negative effect report result operation acquisition dispositionrelate charge amortization expense relate intangible charge impairment long term asset face risk associate global operation adversely affect financial condition result operation operation outside united states accompany certain financial political economic risk include list foreign currency exchange approximately product sale outside united states significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate overall net receiver foreign currency benefit weak dollar adversely affect strong dollar use foreign currency exchange forward option contract hedge percentage forecast international sale hedging program eliminate exposure currency fluctuation predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline antibribery subject foreign corrupt practice act similar worldwide antibribery law govern international operation respect payment government official international operation heavily regulate require significant interaction foreign official policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom possible certain practice challenge law addition despite training compliance program internal control policy procedure protect reckless criminal act commit employee agent enforcement activity antibribery law subject administrative legal proceeding action result civil criminal sanction include monetary penalty exclusion health care program risk inherent conduct global business include international operation include use thirdparty manufacturer distributor collaboration arrangement outside united states expose increase risk theft intellectual property proprietary technology particularly jurisdiction robust intellectual property protection united states restrictive government action intellectual property foreign asset nationalization expropriation imposition compulsory license subject protective economic policy take foreign government trade protection measure import export licensing requirement result imposition trade sanction similar restriction united states government operation adversely affect instability disruption destruction geographic region operate regardless cause include war terrorism social unrest political change instability example january united kingdom uk withdraw european union eu initiate transition period uk eu negotiate future relationship uncertainty concern change law regulation govern conduct clinical trial market medicinal product uk follow countrys exit eu uncertainty lead significant complexity risk company ability research develop market medicinal product eu uk business disruption natural manmade disaster adversely affect revenue materially reduce earning encounter risk global operation adversely affect adverse effect overall business result operation significant safety issue arise market product product candidate reputation harm future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem medicine expect continue find new issue relate safety resistance drug interaction issue require change product label additional warning contraindication narrow indication occur reduce market acceptance sale product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information clinical trial datum directly available public website mean periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action potentially cause product sale stock price decline safety resistance drug interaction issue arise market product sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda european medicines agency ema comparable regulatory agency country continue clinical trial product currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture safety report promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement include related promotion manufacturing subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk certain circumstance required implement risk evaluation mitigation strategy program product include medication guide patient package insert communication plan healthcare provider restriction distribution use product element fda deem necessary assure safe use drug failure comply requirement impose fda result significant civil monetary penalty operating result adversely affect face risk clinical trial include potential unfavorable result delay anticipate timeline disruption adversely affect prospect future revenue growth result operation require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product example february announce kite program antib cell maturation antigen evaluate treatment multiple myeloma move forward recently announce stellar stellar phase study evaluate safety efficacy selonsertib treatment nonalcoholic steatohepatitis nash meet prespecifie week primary endpoint product candidate fail achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth result operation adversely impact example face numerous risk uncertaintie product candidate include filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis psoriatic arthritis glpg treatment idiopathic pulmonary fibrosis cilofexor treatment primary sclerose cholangitis axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth result operation adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn adversely affect result operation harm business addition extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent thirdparty contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit train program management patient enrollment ongoing monitoring site management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely affect depend relationship party sale marketing performance technology development logistic commercialization product failure maintain relationship poor performance company dispute party negatively impact business rely number collaborative relationship party sale marketing performance certain territory example collaboration arrangement janssen sciences ireland uc odefsey compleraeviplera symtuza country rely international distributor sale certain product relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline addition rely thirdparty site collect patient white blood cell know apheresis center shipper courier hospital logistical collection patient white blood cell ultimate delivery yescarta patient disruption difficulty encounter vendor result product loss regulatory action harm yescarta business reputation ensure apheresis center prepare ship cell manufacture facility plan conduct quality certification apheresis center apheresis center choose participate certification process unable complete certification timely manner delay restrain manufacturing commercialization effort result sale yescarta limit harm result operation success depend significant degree ability defend patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret internal knowhow defend infringement patent effort invalidate operate infringe intellectual property properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent file application direct technology subject patent application addition competitor file patent application cover technology participate litigation postgrant proceeding patent trademark office uspto proceeding determine right patent validity patent grant litigation postgrant proceeding uspto proceeding unpredictable expensive divert management attention operation ultimately successful result operation adversely affect event generic manufacturer seek continue seek fda approval market generic version product abbreviate new drug application anda application process typically manufacturer seek approval generic drug description anda litigation note commitment contingency note consolidated financial statement include ii item annual report entry generic version product future lead market share price erosion negative impact business result operation success depend large ability operate infringe patent proprietary right party find infringe valid patent party require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license commercially reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel bictegravir require pay significant damage royalty payment result ongoing litigation relate yescarta biktarvy description litigation sofosbuvir axicabtagene ciloleucel bictegravir tdf taf combination ftc use preexposure prophylaxis note commitment contingency note consolidated financial statement include ii item annual report furthermore rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor certain party comply confidentiality agreement adequate remedy breach trade secret internal knowhow technological innovation know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret internal knowhow technological innovation confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect manufacturing problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation order generate revenue product able produce sufficient quantity product satisfy demand product result complex manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation product manufacture facility thirdparty manufacturer corporate partner depend party perform manufacturing activity effectively timely basis majority solid dose product thirdparty manufacturer corporate partner subject good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect jurisdiction thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval write cost manufacturing batch fail pass quality inspection meet regulatory approval addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product able locate additional replacement facility reasonable basis sale product adversely impact reliance limit number facility extent risk materialize affect performance obligation financial result adversely affect manufacturing operation subject routine inspection regulatory agency unable remedy deficiency cite fda inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate delay production market product interrupt anticipate revenue stock price adversely affect able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture sell product unable purchase sufficient quantity material find suitable alternative material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name new drug application marketing authorization application file regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition deliverie material supplier interrupt reason unable ship certain product commercial supply supply product candidate development clinical trial addition product material utilize operation manufacture facility able replace timely manner commercially reasonable term problem single supplier depend include event disaster earthquake equipment failure difficulty negatively impact development commercialization effort significant portion raw material intermediate manufacture antiviral product supply thirdparty manufacturer corporate partner outside united states result political economic factor specific country region include change interpretation trade regulation compliance requirement tax legislation limit prevent party outside united states supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result encounter difficulty ability conduct clinical trial product candidate manufacture sell product impair adverse effect business import country product available low price unapprove generic counterfeit version product negative impact reputation business price product base local market economic competition differ country country sale country relatively high price reduce product import resold country low price market hiv hbv hcv product agree available substantially reduce price certain low middleincome country participate gilead access program reexporte united states europe high price market revenue adversely affect addition enter agreement generic drug manufacturer license agreement medicine patent pool unite nationsbacke public health organization allow generic drug manufacturer manufacture certain generic version product distribution certain low middleincome country generic version product produce andor distribute agreement reexporte united states europe high price market revenue adversely affect european union require permit product purchase eu member state sell eu member state purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business additionally use divert product occur country approve patient source product outside legitimate supply chain product handled ship store inappropriately affect efficacy product harm patient brand commercial scientific reputation product aware existence buyer club world promote personal importation generic version hcv hiv product approve use country import result patient risk take unapproved medication purport potency claim contain harmful substance extent patient unapproved generic version medication injure generic product brand commercial scientific reputation hcv hiv product harm party illegally distribute sell counterfeit version product meet rigorous quality standard manufacturing supply chain actively action discourage distribution sale counterfeit product world include work local regulatory legal authority enforce law counterfeit drug raise public awareness danger counterfeit drug promote public policy hinder sale availability counterfeit drug counterfeit drug pose risk patient health safety raise risk product recall reputation business suffer result counterfeit drug sell brand name expensive litigation government investigation increase expense continue reduce earning involve number litigation investigation disputerelate matter require expend substantial internal financial resource expect matter continue require high level internal financial resource foreseeable future matter reduce continue reduce earning require significant management attention description litigation investigation disputerelate matter note commitment contingency note consolidated financial statement include ii item annual report require pay significant damage royalty payment result ongoing litigation relate yescarta biktarvy outcome legal proceeding legal proceeding bring investigation investigation initiate disputerelate matter inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business reputation face significant liability result product liability materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company limited insurance product liability arise claim exceed coverage financial condition adversely affect addition negative publicity associate claim regardless merit decrease future demand product impair financial condition description product liability matter note commitment contingency note consolidated financial statement include ii item annual report form k fail attract develop retain highly qualified personnel business operation adversely affect future success depend large continue ability attract develop retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term ability depends maintain strong workplace culture attractive employee particularly leadership transition currently experience additionally change immigration work authorization law regulation difficult employee work transfer jurisdiction operation impair ability attract retain qualified personnel unsuccessful recruitment development retention effort fail maintain strong workplace culture business reputation harmed recently significant change senior leadership team appoint daniel oday chairman chief executive officer andrew dickinson chief financial officer johanna merci chief commercial officer merdad parsey chief medical officer brett pletcher executive vice president corporate affairs general counsel jyoti mehra executive vice president human resources christi shaw chief executive officer kite change management key personnel lead potential organizational realignment additional personnel change disrupt business adversely affect operation business disruption natural manmade disaster adversely affect revenue materially reduce earning worldwide operation thirdparty manufacturer corporate partner subject business interruption stem natural manmade disaster climate change terrorist attack armed conflict earthquake hurricane flooding fire actual threaten public health emergency effort take party prevent mitigate disaster public safety power shutoff facility shutdown uninsured inadequately insure corporate headquarters foster city santa monica location house majority rd activity san dimas la verne oceanside el segundo manufacturing facility locate california seismically active region carry adequate earthquake insurance significant recovery time require resume operation financial condition operating result materially adversely affect event major earthquake dependent information technology system infrastructure datum subject cyberattack security breach legal claim dependent information technology system infrastructure datum include kite konnect platform critical ensure chain identity chain custody yescarta multitude complexity computer system inherently vulnerable service interruption destruction malicious intrusion random attack likewise datum privacy security breach employee pose risk sensitive datum include intellectual property trade secret personal information employee patient customer business partner expose unauthorized person public cyberattack increase frequency sophistication intensity cyberattack include deployment harmful malware denialofservice social engineering mean affect service reliability threaten datum confidentiality integrity availability business technology partner face similar risk security breach system adversely affect security posture invest continue invest protection datum information technology infrastructure assurance effort effort partner vendor prevent future service interruption identify breach system interruption breach adversely affect business operation andor cause loss critical sensitive information include personal information result financial legal business reputational harm addition insurance sufficient type cover financial legal business reputational loss result interruption breach system regulator globally impose new datum privacy security requirement include new great monetary fine privacy violation example general datum protection regulation gdpr effective europe establish regulation handle personal datum non compliance gdpr result monetary penalty percent worldwide revenue addition new domestic datum privacy security law california consumer privacy act ccpa effective january passed similarly introduce requirement respect personal information noncompliance ccpa result liability private action subject statutorily define damage event certain datum breach enforcement gdpr ccpa change new law regulation associate enhance protection personal information include case healthcare datum personal information greatly increase cost provide product service prevent offer certain service jurisdiction operate change effective income tax rate reduce earning subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative regulatory change material adverse impact result operation example united states enact significant tax reform certain provision new law complex continue significantly affect addition significant judgment require determine worldwide provision income taxis factor favorable unfavorable effect income tax rate include limited portion nontax deductible annual brand prescription drug fee accounting stock option sharebase award merger acquisition future level rd spending ability maintain manufacture operational activity irish facility change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate result operation income tax return subject audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period assurance continue pay dividend repurchase stock board director authorize dividend program intend pay quarterly dividend share subject quarterly declaration board director quarter board director approve repurchase billion common stock program billion available repurchase december quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction future declaration time dividend andor time stock repurchase subject capital availability determination board director cash dividend andor stock repurchase good interest stockholder compliance respective law agreement applicable declaration payment cash dividend repurchase stock ability pay dividend andor repurchase stock depend factor cash balance potential future capital requirement strategic transaction include acquisition debt service requirement result operation financial condition factor control board director deem relevant reduction elimination dividend payment dividend program andor stock repurchase negative effect stock price item b unresolved staff comment applicable item property corporate headquarters locate foster city california house administrative certain rd activity rd facility emeryville oceanside santa monica california gaithersburg maryland seattle washington edmonton canada amsterdam netherlands principal manufacturing facility el segundo la verne oceanside san dimas california edmonton canada cork ireland hoofddorp netherland information manufacture facility item business manufacture facility global operation include office europe north america asia south america africa australia middle east believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include ii item annual report incorporate reference item safety disclosure applicable ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild february approximately stockholders record common stock performance graph follow graph compare cumulative total stockholder return past year index standard poor stock index sp index nasdaq biotechnology index nbi index stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index sp index december assume dividend reinveste equity compensation plan information follow table provide certain information respect equity compensation plan effect december millions share amount number common share remain available future issuance equity number common share weightedaverage compensation plan issue exercise exercise price exclude security outstanding option warrant outstanding option reflect column right warrant right plan category b c equity compensation plan approve security holder equity incentive plan employee stock purchase plan total equity compensation plan approve security holder equity compensation plan approve security holder total account million restrict stock unit performance share award unit phantom share exercise price grant equity incentive plan employee stock purchase plan participant permit purchase common stock discount certain date payroll deduction predetermine purchase period accordingly number determinable issuer purchase equity security quarter board director authorize billion share repurchase program program repurchase open market privately negotiate transaction repurchase retire million share common stock billion open market transaction program table summarize stock repurchase activity month end december thousands share amount maximum fair total number value share total number average share purchase share price pay publicly purchase purchase share announce program program october october november november december december total difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock unit award order satisfy applicable tax withholding obligation quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction item select financial datum gilead sciences inc select consolidated financial datum million share amount year end december consolidated statement income datum total revenue total cost expense income operation provision income taxis net income net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute cash dividend declare share december consolidated balance sheet datum cash cash equivalent marketable debt security work capital total asset longterm obligation longterm debt include current portion retain earning total stockholder equity management discussion analysis financial condition result operation include item annual report description result operation adopt accounting standard update topic revenue contract customer modify retrospective method result report period begin january present topic prior period amount adjust continue report accordance historical accounting topic revenue recognition december record defer tax benefit billion relate intangible asset transfer foreign subsidiary ireland united states record defer tax charge million relate transfer acquire intangible asset foreign subsidiary united states december record estimate billion net charge relate enactment tax cut job act tax reform tax reform lower corporate tax rate united states effective tax year begin december note income taxis note consolidated financial statement include item annual report additional detail investment equity security equity method investment elect fair value method accounting record fair market value fair value readily determinable begin january unrealize gain loss include income expense net consolidated statement income period present prior january unrealize gain loss include accumulate comprehensive income separate component stockholder equity repay billion principal senior unsecured note maturity repay billion principal senior unsecured note maturity repay billion term loan borrow connection acquisition kite pharma inc connection acquisition kite pharma inc issue billion aggregate principal senior unsecured note borrow billion aggregate principal term loan facility credit agreement billion repay issue billion principal senior unsecured note repay million principal balance convertible senior note million principal balance senior unsecured note maturity issue billion principal senior unsecured note repay million principal balance convertible senior note maturity adopt accounting standard update topic lease require lessee recognize rightofuse asset lease liability operating lease lease term great year adopt topic modify retrospective method result report period begin january present topic prior period amount adjust continue report accordance historical accounting topic lease note organization summary significant accounting policy note lease note consolidated financial statement include item annual report information item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor additional information relate comparison result operation year include item management discussion analysis financial condition result operation file sec incorporate reference annual report consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include viral disease inflammatory fibrotic disease oncology seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategic collaboration portfolio market product include ambisome atripla biktarvy cayston compleraeviplera descovy descovy prep emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvada prep tybost vemlidy viread vosevi yescarta zydelig sell distribute authorize generic version epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain product corporate partner collaborative agreement business highlight financial performance solid growth hiv franchise continue drive result take significant step position future growth include important research development rd collaboration introduction new corporate strategy hire key member executive leadership team develop new corporate strategy guide work seek drive growth decade ambitious goal launch new transformative therapy year continue progress pipeline currently clinicalstage program program registrational label enable study program receive breakthrough therapy designation food drug administration fda achieve sale billion hiv franchise increase reach alltime high continue revenue growth hiv product drive demand biktarvy increase number individual take product preexposure prophylaxis prep end biktarvy available major market united states approximately individual prep receive descovy enter transformative rd collaboration galapagos nv galapagos july build exist partnership effectively enable double rd footprint accelerate development novel treatment inflammatory fibrotic disease submit regulatory filing filgotinib fda compound priority review rheumatoid arthritis ra submit filgotinib approval europe japan actively prepare competitive launch region galapago continue advance phase study glpg treatment idiopathic pulmonary fibrosis regard nonalcoholic steatohepatitis nash stellar atlas study fail reach primary endpoint continue work understand result determine appropriate step therapy include potential combination therapeutic approach cell therapy kite gilead company kite submit ktex regulatory approval united states europe treatment relapse refractory mantle cell lymphoma mcl approve kite company cell therapy market continue demonstrate efficacy yescarta data share end show approximately half patient treat yescarta refractory large bcell lymphoma alive year follow treatment zuma study confirm yescartas benefitrisk profile addition cell therapy continue grow research portfolio immunooncology business expand geographically include china product approve product vemlidy epclusa harvoni genvoya list national reimbursement drug list effective january continue advance product pipeline therapeutic area goal deliver bestinclass drug potential improve live patient illness key corporate product pipeline update include viral disease license collaboration agreement rockefeller university novartis ag lyndra therapeutics inc approval vosevi biktarvy china national medical product administration approval prep indication descovy fda approval biktarvy epclusa japans ministry health labour welfare mhlw inflammatory fibrotic disease collaboration kyverna therapeutics inc glympse bio inc renown institute health innovation goldfinch bio inc insitro inc novo nordisk yuhan corporation agreement eisai co ltd distribution copromotion filgotinib japan pende regulatory approval japans mhlw treatment ra submission new drug application nda priority review fda submission nda japans mhlw filgotinib topline result phase atlas study combination monotherapy investigational treatment patient bridge fibrosis f compensate cirrhosis f nash study meet primary endpoint continue analyze atlas data determine appropriate step therapies collaboration galapagos equity investment galapago gain access galapago current future product portfolio note collaborative arrangement note consolidated financial statement include item annual report additional information european medicine agencys validation marketing authorization application filgotinib application evaluation agency oncology fda acceptance biologic license application grant priority review designation ktex treatment adult patient relapse refractory mcl european medicine agencys validation marketing authorization application ktex application evaluation agency collaboration carna biosciences inc nurix therapeutics inc humanigen inc kiniksa pharmaceuticals ltd leadership change place diverse highly experienced leadership team senior leadership change include appointment daniel p oday chairman chief executive officer andrew dickinson executive vice president chief financial officer merdad v parsey chief medical officer christi l shaw chief executive officer kite johanna merci chief commercial officer departure john g mchutchison chief scientific officer head research development gregg h alton chief patient officer katie l watson executive vice president human resource plan retirement robin l washington role executive vice president chief financial officer donation centers disease control prevention million bottle truvada descovy annually uninsure americans risk hiv financial highlight total revenue increase billion total product sale increase billion compare billion billion respectively primarily high sale hiv product partially offset low sale ranexa letairis hcv product united states product sale billion compare billion europe product sale billion compare billion product sale international location billion compare billion cost good sell decrease billion compare billion primarily million low royalty expense low amortization expense relate intangible asset associate ranexa partially offset high inventory writedown record write down million million respectively slow move excess raw material work process inventory primarily low longterm demand hcv product rd expense increase billion compare billion primarily upfront collaboration licensing expense billion relate collaboration galapago high personnel cost largely support cell therapy business partially offset lower stockbase compensation expense record impairment charge million million respectively relate inprocess rd iprd intangible asset acquire connection acquisition kite pharma inc sell general administrative sga expense increase billion compare billion primarily promotional expense united states expense associate expansion business japan china partially offset low stockbase compensation expense net income attributable gilead change billion diluted share compare billion diluted share primarily pretax upfront collaboration licensing expense billion relate collaboration galapago partially offset net favorable fluctuation tax effect intraentity intangible asset transfer different tax jurisdiction increase net unrealized gain equity security yearoveryear dilute earning share favorably impact stock repurchase activity december billion cash cash equivalent marketable debt security compare billion december generate billion operate cash flow pay billion connection collaboration equity investment galapago classify cash flow investing activity repay billion principal debt pay cash dividend billion utilize billion repurchase common stock strategy outlook focus create possibility patient scientific breakthrough innovation leverage pillar durable core business exist pipeline opportunity strategy drive additional growth strategy include ambition priority enable achieve ambition strategic ambition define success look like decade summarize bring transformative therapy patient ii biotech employer partner choice iii deliver shareholder value sustainable responsible manner strategic priority reflect deliver ambition expand internal external innovation ii strengthen portfolio strategy decision make iii increase patient benefit access iv continue evolve culture expect underlying growth base business expect offset fullyear impact cardiopulmonary product loss exclusivity occur initial generic version truvada united states late continue invest support growth biktarvy descovy prep launch preparation competitive launch filgotinib ra united states japan europe continue investment pipeline cell therapy external partnership overall plan guide newly establish corporate strategy provide focus guide resource capital allocation priority expect datum readout include filgotinib ulcerative colitis ktex acute lymphoblastic leukemia axicabtagene ciloleucel cd indolent bcell nonhodgkin lymphoma inhl second line diffuse large bcell lymphoma glpg osteoarthritis augment product pipeline continue pursue opportunity collaboration partnership strategic investment fit longterm strategic plan progress initiative subject number uncertainty include limited possibility unfavorable result new ongoing clinical trial continuation uncertain global macroeconomic environment additional pricing pressure payer competitor slow anticipate growth hiv product increase discount chargeback rebate ongoing contract future negotiation commercial government payer market share price erosion cause introduction generic version product contain tenofovir disoproxil fumarate tdf outside united states viread letairis ranexa united states inaccuracy hcv patient start estimate potential amendment affordable care act government action effect lower price largerthan anticipate shift payer mix highly discount payer segment volatility foreign currency exchange rate result operation total revenue follow table summarize periodoverperiod change revenue million percentage change change revenue product sale royalty contract revenue total revenue product sale compare total product sale increase billion compare billion primarily high sale hiv product partially offset low sale ranexa letairis hcv product hiv product sale increase billion compare billion primarily high sale volume result continue uptake biktarvy increase partially offset decrease sale volume genvoya truvada emtricitabine ftctdfbase product low average net selling price hcv product sale decrease billion compare billion primarily low average net selling price include decline medicare price yescarta sale increase million compare million primarily high number therapy provide patient continue expansion europe product sale include vemlidy viread letairis ranexa zydelig ambisome cayston decrease billion compare billion primarily expect decline sale ranexa letairis entry generic version united states early total product sale generate outside united states face exposure movement foreign currency exchange rate primarily euro foreign currency exchange contract hedge percentage foreign currency exposure foreign currency exchange net hedge immaterial impact product sale base comparison foreign currency exchange rate record product sale net estimate government rebate chargeback cash discount prompt payment distributor fee relate cost deduction generally refer grosstonet deduction total billion gross product sale compare billion gross product sale billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee relate cost product sale united states increase billion compare billion primarily high sale hiv product partially offset low sale ranexa letairis follow entry generic version low sale hcv product increase sale hiv product primarily continued uptake biktarvy increase number individual take prep partially offset decrease sale volume hiv product include genvoya atripla stribild decrease sale hcv product primarily low average net selling price include decline medicare price product sales europe decrease billion compare billion primarily low sale hcv product broad availability generic version truvada atripla decrease sale hcv product primarily lower patient start low average net selling price decrease partially offset continue uptake biktarvy odefsey yescarta favorable net adjustment government rebate relate sale prior year product sale international location increase billion compare billion primarily high hiv product sale japan result acquire right certain product hiv portfolio japan effective january higher hcv product sale japan launch epclusa follow table summarize periodoverperiod change product sale million percentage change change atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza total hiv ambisome ledipasvirsofosbuvir letairis ranexa sofosbuvirvelpatasvir vemlidy viread vosevi yescarta zydelig total product sale percentage great include emtriva tybost represent revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fix dose combination product commercialize janssen sciences ireland uc amount consist sale harvoni authorize generic version harvoni sell separate subsidiary asegua therapeutics llc amount consist sale epclusa authorize generic version epclusa sell separate subsidiary asegua therapeutics llc include cayston hepsera sovaldi follow additional discussion sale hiv hcv product descovy ftctafbase product biktarvy descovy genvoya odefsey revenue share symtuza follow table summarize periodoverperiod change sale descovy ftctafbase product million percentage change change europe location total total product sale hiv product sale descovy ftctafbase product sale increase major market compare increase united states europe primarily high demand shift product mix biktarvy increase international location primarily high product sale japan result acquire right certain product hiv portfolio japan effective january truvada ftctdfbase product atripla compleraeviplera stribild truvada follow table summarize periodoverperiod change sale truvada ftctdfbase product million percentage change change europe location total total product sale truvada ftctdfbase product sale decrease united states europe compare decrease sale primarily low sale volume result patient switch new regimen contain ftctaf partially offset increase usage truvada prep decrease europe sale primarily low sale volume truvada atripla result broad availability generic version patient switch new regimen contain ftctaf expect decline sale truvada united states patient switch descovy prep truvada prep expect entry generic version late hcv product epclusa harvoni sovaldi vosevi authorize generic epclusa harvoni follow table summarize periodoverperiod change sale hcv product million percentage change change europe location total total product sale decrease hcv product sale united states compare primarily low average net selling price include decline medicare price decrease hcv product sale europe compare primarily lower patient start low average net selling price partially offset favorable net adjustment government rebate discount relate sale prior year decrease hcv product sale international location compare primarily low sale sovaldi partially offset high sale epclusa cost good sell product gross margin follow table summarize periodoverperiod change product sale cost good sell product gross margin million percentage change change total product sale cost good sell product gross margin cost good sell decrease million compare primarily low royalty expense low amortization expense relate intangible asset associate ranexa fully amortize quarter partially offset high inventory writedown record inventory writedown million million relate slow move excess raw material work process inventory primarily low longterm demand hcv product record inventory writedown million million relate excess raw material primarily sustained decrease demand harvoni result shift market harvoni epclusa royalty expense decrease million compare primarily low sale atripla ranexa letairis product contain elvitegravir research development expense follow table summarize periodoverperiod change rd expense million percentage change change rd expense rd expense consist primarily clinical study perform contract research organization material supply payment collaborative arrangement include upfront milestone payment license fee expense reimbursement collaboration partner iprd impairment charge personnel cost include salary benefit stockbase compensation expense overhead allocation consist support infrastructure cost track total rd expense product candidate therapeutic area development phase manage rd expense identify rd activity anticipate perform give period prioritize effort base scientific datum probability technical regulatory successful development market potential available human capital resource consideration continually review rd project base unmet medical need necessary reallocate resource internal rd portfolio external opportunity believe good support longterm growth business follow table provide breakout rd expense major cost type million percentage change change upfront collaboration licensing expense personnel infrastructure expense clinical study outside service iprd impairment charge stockbase compensation expense total percentage great rd expense increase billion compare primarily billion upfront collaboration licensing expense relate collaboration galapago high personnel cost largely support cell therapy business increase investment research project partially offset lower stockbase compensation expense record impairment charge million relate iprd intangible asset acquire connection acquisition kite pharma inc primarily treatment indolent nonhodgkin lymphoma largely drive change estimate market opportunity new therapy combination exist therapy approve record impairment charge million relate iprd intangible asset kite program antib cell maturation antigen evaluate treatment multiple myeloma discontinuance stockbase compensation expense decrease million compare primarily impact stockbase compensation expense associate acquisition kite pharma inc sell general administrative expense follow table summarize periodoverperiod change sga expense million percentage change change sga expense sga expense relate sale marketing finance human resource legal administrative activity expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include brand prescription drug bpd fee united states pharmaceutical manufacturer brand drug product require pay portion bpd fee estimate base select government sale prior year percentage total industry government sale truedup receipt invoice internal revenue service sga expense increase million compare primarily high promotional expense united states expense associate expansion business japan china partially offset low stockbase compensation expense stockbase compensation expense decrease million compare primarily impact stockbase compensation expense associate acquisition kite pharma inc bpd fee expense million million million respectively bpd fee expense taxdeductible income expense net follow table summarize periodoverperiod change income expense net million percentage change change income expense net change income expense net compare primarily high net unrealized gain billion change fair value equity security largely relate equity investment galapago start january record unrealized gain loss change fair value marketable equity security income expense net consolidated statement income result adoption accounting standard update financial instrument overall recognition measurement financial asset financial liability provision income taxis follow table summarize periodoverperiod change provision income taxis million percentage change change effective tax rate provision income taxis decrease effective tax rate provision income taxis compare primarily billion deferred tax benefit relate intangible asset transfer foreign subsidiary ireland united states effective tax rate include million defer tax charge result transfer acquire intangible asset foreign subsidiary united states decrease effective tax rate provision income taxis compare primarily billion net tax charge reduction corporate tax rate result enactment tax cut job act tax reform december effective tax rate decrease million tax benefit record relate settlement tax examination offset million defer tax charge discuss change geographic mix earning tax global intangible lowtaxed income enact tax reform note income taxis note consolidated financial statement include item annual report additional detail tax reform liquidity capital resource follow table summarize cash cash equivalent marketable debt security working capital december million cash cash equivalent marketable debt security work capital cash cash equivalent marketable debt security cash cash equivalent marketable debt security decrease billion compare december generate billion operate cash flow pay billion connection collaboration equity investment galapago repay billion debt pay cash dividend billion repurchased million share common stock billion open market transaction work capital working capital decrease billion compare december primarily use cash note head cash cash equivalent marketable debt security cash flow follow table summarize cash flow activity million cash provide operating activity invest activity financing activity cash provide operating activity cash provide operating activity represent cash receipt disbursement related activity invest financing activity operate cash flow derive adjust net income noncash item change operate asset liability cash provide operating activity increase million billion compare primarily low tax payment partially offset low collection account receivable collection receivable bristolmyers squibb company follow termination collaboration pursuant term exist agreement tax payment include million payment relate annual installment tax reform transition tax million deem early payment tax reform transition tax million settlement tax examination start upfront milestone payment relate collaborative arrangement classify cash flow investing activity consolidate statement cash flow comparative prior year amount material reclassify investing activity operating activity cash provide investing activity cash provide investing activity primarily consist purchase sale maturity marketable debt security capital expenditure milestone payment relate collaborative arrangement purchase equity security investment cash investing activity billion compare cash provide investing activity billion change cash provide investing activity primarily high purchase marketable debt security billion payment connection collaboration equity investment galapago partially offset high proceed sale marketable debt security high purchase marketable debt security result shift investment strategy invest long date security compare addition pay japan tobacco inc million connection acquire right market distribute certain hiv product japan cash provide investing activity billion compare cash investing activity billion change cash provide investing activity primarily high proceed maturitie marketable debt security low purchase marketable debt security partially offset low proceed sale marketable debt security addition billion cash acquire kite pharma inc cash business combination cash provide financing activity cash financing activity decrease billion billion compare primarily billion low repayment debt billion low repurchase common stock cash financing activity billion compare cash provide financing activity billion change cash provide financing activity primarily high repayment debt repurchase common stock addition billion net proceed debt issuance partially fund acquisition kite pharma inc debt issue debt credit facility repay maturity billion billion principal senior unsecured note respectively addition repay billion borrow term loan facility credit agreement time term loan facility credit agreement terminate february repay maturity million principal senior unsecured note december amount outstanding billion fiveyear revolve credit facility mature require comply certain covenant note indentures december violation covenant summary borrowing financing arrangement include note debt credit facility note consolidated financial statement include item annual report capital return program detail stock repurchase program dividend include note stockholder equity note consolidated financial statement include item annual report stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction start repurchase program april repurchase program million million share common stock billion billion respectively december remain authorize repurchase program billion quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction dividend declare pay quarterly cash dividend aggregate billion share common stock billion share common stock respectively february announce board director declare quarterly cash dividend increase share common stock payment date march stockholders record close business march future dividend subject declaration board director capital resource believe exist capital resource supplement cash flow generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability possibility acquire additional manufacturing capability office facility possibility acquire company new product debt service requirement establishment additional collaborative relationship company cost associate defense settlement adverse result government investigation litigation future require additional funding form proceed equity debt financing fund require guarantee available favorable term critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement include item annual report prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale control product transfer generally shipment delivery customer certain case correspond sale customer party recognition revenue product sale provision form variable consideration include government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate variable consideration include net sale price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve government rebate chargeback represent majority variable consideration require complex significant judgment management estimate assess period update reflect current information government rebate chargeback government rebate chargeback include amount pay payer healthcare providers united states include medicaid rebate aids drug assistance program rebate chargeback veterans administration public health service chargeback rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price allowance government rebate chargeback estimate base product sell historical payer mix available pertinent party industry information estimate patient population know market event trend product sale channel inventory datum obtain major wholesaler accordance inventory management agreement consideration available new information change program regulation guideline impact actual rebate andor expectation future payer mix program believe methodology use estimate government rebate chargeback reasonable appropriate give current fact circumstance actual result differ significantly estimate historically actual government rebate chargeback claim prior period vary estimate government chargeback payable direct customer classify reduction account receivable consolidated balance sheet total million million december respectively government rebate payable party payer healthcare provider record accrue government rebate consolidated balance sheet total billion billion december respectively follow table summarize consolidated activity end balance government rebate chargeback account balance decreaseincrease balance end million begin year product sale payment year year end december activity relate sale activity relate sale prior total year end december activity relate sale activity relate sale prior total legal contingency party legal action significant describe note commitment contingency legal proceeding note consolidated financial statement include item annual report possible determine outcome matter recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine loss reasonably possible loss range loss estimate disclose possible loss significant judgment require determination probability determination exposure reasonably estimable inherent uncertainty unpredictability relate matter accrual base believe good information available time assessment include legal fact circumstance case status proceeding applicable law view legal counsel final resolution matter possible loss excess record amount material adverse effect result operation cash flow financial position periodically reassess matter additional information available adjust estimate assumption fact circumstance indicate need change material accrual consolidated balance sheet matter december valuation intangible asset acquire expect continue acquire intangible asset acquisition consolidation variable interest entity identifiable intangible asset measure respective fair value acquisition date subject revision measurement period year acquisition date fair value asset generally determine probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar profile represent rate market participant use value intangible asset discount cash flow model value intangible asset require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability technical regulatory success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market believe fair value record intangible asset acquire base reasonable estimate assumption give fact circumstance relate valuation date intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort period asset consider indefinitelive amortize development complete generally occur regulatory approval market product obtain associate asset deemed finitelive amortize base respective estimate useful life point time primarily straightline basis intangible asset review impairment annual basis annual test aware event change indicate likely fair value intangible asset andor iprd project respective carrying amount perform quantitative impairment assessment calculate fair value discount cash flow model require significant estimate assumption similar methodology determine acquisition date fair value intangible asset describe carry value intangible asset exceed fair value intangible asset writtendown fair value significant judgment employ determine estimate assumption change estimate assumption significant impact result operation give period example recognize million impairment charge relate iprd project primarily treatment indolent nonhodgkin lymphoma change estimate market opportunity major risk uncertainty associate iprd project require obtain regulatory approval order able market product approval require complete clinical trial demonstrate product candidate safe effective consequently eventual realize value acquire iprd project vary fair value date acquisition iprd impairment charge occur future period material adverse effect result operation example conclude kite program acquire connection acquisition kite pharma inc justify effort base totality clinical datum gather discontinue program result carry value iprd relate kite program write zero record impairment charge million note intangible asset note consolidated financial statement include item annual report additional information impairment charge related indefinitelive iprd intangible asset provision income taxis estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law example united states enact significant tax reform certain provision new law continue significantly affect predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period note income taxis note consolidated financial statement include item annual report additional information balance sheet arrangement balance sheet arrangement define item aii regulation sk contractual obligation contractual obligation represent future cash commitment relate significant enforceable legally bind obligation certain purchase obligation likely continue regardless fact cancelable expect timing payment amount present estimate base exist contract reflect future modification termination exist contract anticipate potential new contract follow table summarize aggregate maturity contractual obligation december payment period million total debt operating lease obligation purchase obligation transition tax payable total debt consist senior unsecured note include principal future interest payment interest payment fix rate senior unsecured note incur calculate base term relate note note debt credit facility note consolidated financial statement include item annual report additional information note lease note consolidated financial statement include item annual report additional information amount primarily relate capital commitment active pharmaceutical ingredient api minimum purchase commitment certain inventoryrelate item advertising rd commitment significant rd commitment relate clinical study perform contract research organization cro exclude table material cro contract cancelable addition table reflect approximately million additional minimum purchase commitment result api contract amend january connection tax reform record federal income tax payable transition tax mandatory deem repatriation foreign earning payable eightyear period amount include table represent remain federal income tax payable december december longterm income taxis payable include unrecognized tax benefit interest penalty total billion high degree uncertainty time future cash settlement event extinguish unrecognized tax benefit unable estimate period cash settlement exclude unrecognized tax benefit commit potential future milestone payment party license collaboration development arrangement payment agreement generally contingent certain future event include achievement certain developmental regulatory commercial milestone achievement event probable reasonably estimable potential payment record consolidated balance sheet include table recent accounting pronouncement information require item include note organization summary significant accounting policy note consolidated financial statement include item annual report item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk market price reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation country worldwide result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business approximately product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december december resulted reduction fair value contract approximately million million respectively date realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale debt security fix rate longterm debt create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december expect maturity million total fair percentage total value asset availableforsale debt security average interest rate liability fix rate long term debt include current portion average interest rate amount represent principal balance addition fix rate longterm debt billion fiveyear revolve credit facility mature amount outstanding year revolve credit facility december note debt credit facility note consolidated financial statement include item annual report additional information market price risk hold share common stock certain publicly trade biotechnology company primarily connection license collaboration agreement equity security measure fair value change fair value recognize earning fair value equity security approximately billion million december respectively change fair value equity security impact volatility stock market change general economic condition factor hypothetical increase decrease stock price equity security increase decrease fair value december approximately million million respectively item financial statement supplementary datum gilead sciences inc index consolidated financial statement supplementary data year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement select quarterly financial information unaudite schedule ii valuation qualifying account report independent register public accounting firm stockholder board director gilead sciences inc opinion financial statement audit accompany consolidated balance sheet gilead sciences inc company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note financial statement schedule list index item collectively refer consolidated financial statement opinion consolidated financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity generally accept accounting principle audit accordance standard public company accounting oversight board united states pcaob companys internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion critical audit matter critical audit matter communicate matter arise current period audit financial statement communicate require communicate audit committee relate account disclosure material financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate government commercial rebate description fully describe note company estimate reduction revenue amount payable payer healthcare matter providers united states government commercial rebate program period relate sale occur rebate vary product payer individual payer plan know point sale estimate reduction revenue base product sell historical payer mix historical discount rate estimate actual datum adjust current period expectation auditing company estimate reduction revenue rebate complex involve significant judgment particularly assess reasonableness estimate payer utilization discount rate apply sale period estimate rely heavily historical datum adjust change utilization discount rate time address evaluate test design operating effectiveness company internal control management estimation matter review reduction revenue rebate program include control assess utilization rate discount rate assumption audit test completeness accuracy datum utilize control accuracy calculation support management estimate test management estimation methodology determine utilization discount rate audit procedure include evaluate evidence contrary estimate amount perform sensitivity analysis rate estimate perform comparison actual payment relate amount accrue current prior year valuation inprocess research development intangible asset description december company inprocess research development iprd intangible asset billion company matter record impairment charge million year discuss note intangible asset indefinite useful life relate purchase iprd project measure respective fair value acquisition date consider indefinitelive completion abandonment associate rd effort company test indefinitelive intangible asset impairment annual basis annual test aware event change indicate fair value asset carry amount auditing impairment test complex significant judgment require estimate fair value iprd intangible asset particular fair value estimate sensitive significant assumption eg discount rate project research development cost probability technical success addressable patient population project market share product profitability affect expect future market economic condition address evaluate test design operating effectiveness company internal control determination matter estimate fair value iprd intangible asset example test control management review valuation model audit significant assumption develop fair value estimate indefinite live intangible asset test management control validate datum fair value estimate complete accurate test estimate fair value company iprd intangible asset audit procedure include evaluate company use appropriate valuation methodology assistance valuation specialist test significant assumption discuss test completeness accuracy underlie datum example compare significant assumption current industry market economic trend historical result company business guideline company industry relevant factor addition evaluate probability technical success consider phase development iprd project company history obtain regulatory approval perform sensitivity analysis significant assumption evaluate change estimate fair value iprd intangible asset result change assumption ernst young llp serve company auditor san jose california february gilead sciences inc consolidated balance sheet million share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance respectively inventory prepaid current asset total current asset property plant equipment net longterm marketable security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue liability current portion longterm debt obligation net total current liability longterm debt net longterm income taxis payable longterm obligation commitment contingency note stockholder equity prefer stock par value share share authorize outstanding common stock par value share authorize share issue outstanding respectively additional paidin capital accumulate comprehensive income retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note gilead sciences inc consolidated statement income million share amount year end december revenue product sale royalty contract revenue total revenue cost expense cost good sell research development expense sell general administrative expense total cost expense income operation interest expense income expense net income provision income taxis provision income taxis net income net loss income attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute accompany note gilead sciences inc consolidated statement comprehensive income million year end december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale debt security net unrealize gain net tax reclassification net income net tax net change cash flow hedge net unrealized gain loss net tax reclassification net income net tax net change comprehensive income loss comprehensive income comprehensive loss income attributable noncontrolle interest comprehensive income attributable gilead accompany note gilead sciences inc consolidated statement stockholders equity millions share amount gilead stockholder equity common stock accumulate additional total paidin comprehensive retain noncontrolle stockholder share capital income loss earning interest equity balance december change noncontrolle interest net income comprehensive loss net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share balance december change noncontrolle interest net income comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share cumulative effect adoption new accounting standard balance december net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share cumulative effect adoption new accounting standard note balance december accompany note gilead sciences inc consolidated statement cash flow millions year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense defer income taxis net gain equity security upfront milestone expense relate collaborative arrangement inprocess research development impairment writedown slow move excess raw material work process inventory change operate asset liability account receivable net inventory prepaid expense account payable income taxis payable accrue liability net cash provide operating activity invest activity purchase marketable debt security proceed sale marketable debt security proceed maturitie marketable debt security upfront milestone payment relate collaborative arrangement purchase equity security acquisition net cash acquire capital expenditure net cash provide investing activity financing activity proceed debt finance net issuance cost proceed issuance common stock repurchase common stock repayment debt obligation payment dividend net cash provide financing activity effect exchange rate change cash cash equivalent net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include viral disease inflammatory fibrotic disease oncology seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategic collaboration portfolio market product include ambisome atripla biktarvy cayston compleraeviplera descovy descovy prep emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvada prep tybost vemlidy viread vosevi yescarta zydelig sell distribute authorize generic version epclusa harvoni united states separate subsidiary asegua therapeutics llc addition sell distribute certain product corporate partner collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary certain variable interest entity primary beneficiary intercompany transaction eliminate consolidated entity expose economic record net income loss attributable noncontrolle interest consolidate statement income equal percentage economic ownership interest retain entity respective noncontrolle party assess primary beneficiary variable interest entity vie inception arrangement reporting date assessment base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate significant accounting policy estimate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition january adopt accounting standard update revenue contract customer topic modify retrospective method topic supersede revenue recognition requirement topic revenue recognition topic result change accounting policy revenue recognition detailed policy election practical expedient take account shipping handling activity perform customer obtain control good fulfillment cost separate performance obligation expect contract inception period transfer control correspond payment customer year adjust consideration effect significant financing component product sale recognize revenue product sale control product transfer generally shipment delivery customer certain case correspond sale customer party recognition revenue product sale provision form variable consideration include government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate variable consideration include net sale price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve payment term customer generally range day variable consideration rebate chargeback estimate reduction revenue amount pay payer healthcare providers united states include medicaid rebate aids drug assistance program rebate chargeback veterans administration public health service rebate chargeback foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan estimate base product sell historical payer mix available pertinent thirdparty industry information estimate patient population know market event trend product sale channel inventory datum obtain major wholesaler accordance inventory management agreement consideration available new information change program regulation guideline impact actual rebate andor expectation future payer mix program government chargeback payable direct customer classify reduction account receivable consolidated balance sheet government rebate payable party payer healthcare provider record accrue government rebate consolidated balance sheet cash discount estimate cash discount base contractual term historical customer payment pattern expectation future customer payment pattern distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return typically permit return product damage defective receive customer case product sell united states certain country product expired accept return product expire month expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern historical industry information report return rate similar product contractual agreement intend limit inventory maintain wholesaler royalty contract revenue royalty revenue recognize period obligation satisfied correspond sale corporate partner occur research development expense research development rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply payment collaborative arrangement include upfront milestone payment license option fee expense reimbursement collaboration partner overhead allocation consist support infrastructure cost charge rd cost include clinical study cost expense incur clinical study cost significant component rd expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination sell general administrative expense sell general administrative sga expense relate sale marketing finance human resource legal administrative activity sga expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include brand prescription drug bpd fee united states pharmaceutical manufacturer brand drug product require pay portion bpd fee estimate base select government sale prior year percentage total industry government sale expense cost advertising include promotional expense incur advertising expense million million million year end december respectively cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent marketable nonmarketable security marketable debt security determine appropriate classification marketable debt security time purchase reevaluate designation balance sheet date marketable debt security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale debt security exclude net income report accumulate comprehensive income loss aoci separate component stockholder equity income expense net include interest amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline marketable nonmarketable equity security investment equity security equity method investment record fair market value fair value readily determinable begin january unrealize gain loss include income expense net consolidated statement income period present prior january unrealize gain loss include aoci separate component stockholder equity investment entity significant influence meet requirement consolidation elect fair value option use equity method accounting share underlie income loss entity report income expense net consolidated statement income elect fair value option account equity investment galapagos nv galapagos significant influence believe fair value option well reflect underlying economic investment note collaborative arrangement additional information equity security readily determinable fair value record measurement alternative cost impairment adjust observable price change orderly transaction identical similar investment issuer certain investment equity security nonpublic company account equity method base ownership percentage factor indicate significant influence investee investment equity security readily determinable fair value investment nonpublic company account equity method accounting material period present investment equity security record prepay current asset longterm asset consolidate balance sheet regularly review security indicator impairment concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale trade account receivable record net allowance wholesaler chargeback relate government program cash discount prompt payment doubtful account estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice majority trade account receivable arise product sale united states europe japan date experience significant loss respect collection account receivable believe allowance doubtful account adequate december certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial inventory inventory record low cost net realizable value cost determine firstin firstout basis periodically review inventory identify obsolete slow move excess unsaleable item obsolete slow move excess unsaleable item observe alternate use inventory record writedown net realizable value charge cost good sell consolidated statement income determination net realizable value require judgment include consideration factor estimate future product demand product net selling price current future market condition potential product obsolescence future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor consider include current status regulatory approval process potential impediment approval process safety efficacy anticipate rd initiative impact indication compound viability commercialization marketplace trend property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method repair maintenance cost expense incur estimate useful life year generally follow description estimate useful life building improvement short year useful life laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term acquisition account business combination acquisition method accounting require asset acquire include inprocess research development iprd project liability assume record fair value acquisition date consolidate balance sheet excess purchase price fair value net asset acquire record goodwill determination estimate fair value require significant estimate assumption result record adjustment fair value asset acquire liability assume measurement period year acquisition date correspond offset goodwill transaction cost associate business combination expense incur determine net asset acquire meet definition business combination acquisition method accounting transaction account acquisition asset goodwill record contingent consideration payment achievement developmental regulatory commercial milestone generally recognize acquisition date asset acquisition upfront payment allocate iprd project acquisition date subsequent milestone payment charge expense consolidated statement income alternative future use goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset measure respective fair value acquisition date subject revision measurement period year acquisition date intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort amortize goodwill intangible asset indefinite useful life test goodwill indefinitelive intangible asset impairment annual basis annual test aware event circumstance indicate fair value asset carry amount development successfully complete generally occur regulatory approval obtain associate asset deem finitelived amortize respective estimate useful life begin point time intangible asset finite useful life amortize estimate useful life primarily straightline basis review impairment fact circumstance indicate carry value asset recoverable impairment longlive asset longlive asset include property plant equipment finitelive intangible asset review impairment fact circumstance internally externally indicate carry value asset recoverable indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset carrying asset asset group asset asset group determine impair excess carrying value asset asset group estimate fair value recognize impairment loss foreign currency translation transaction gain loss hedge contract nonus entity operation record functional currency entity result operation nonus dollar functional currency entity translate dollar average currency rate asset liability translate currency rate period end foreign currency translation adjustment record component aoci stockholder equity foreign currency transaction gain loss record income expense net consolidated statement income net foreign currency transaction gain loss material year end december hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrealize gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose fair value financial instrument apply fair value account financial asset liability nonfinancial asset liability recognize disclose fair value financial statement recur basis define fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine fair value measurement asset liability require record fair value consider principal advantageous market transact marketbase risk measurement assumption market participant use price asset liability risk inherent valuation technique transfer restriction credit risk derivative financial instrument recognize derivative instrument asset liabilitie fair value consolidate balance sheet change fair value derivative designate hedge transaction record period current earning aoci change fair value derivative hedge transaction record period current earning assess inception ongoing basis derivative hedging transaction effective offset change cash flow fair value hedge item determine forecast transaction probable occur discontinue hedge accounting affect portion hedge instrument relate unrealized gain loss contract recognize income expense net consolidated statement income income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation applicable tax law regulation record liability relate unrecognized tax benefit accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period elect account tax global intangible lowtaxed income gilti enact tax cut job act tax reform component tax expense period tax incur period cost method presentation cash flow start upfront milestone payment relate collaborative arrangement classify cash flow investing activity consolidate statement cash flow comparative prior year amount material reclassify investing activity operating activity recently adopt accounting pronouncement february financial accounting standard board fasb issue accounting standard update lease asu subsequently issue supplemental adoption guidance clarification collectively topic topic amend number aspect lease accounting include require lessee recognize rightofuse asset lease liability operating lease lease term great year topic supersede topic lease january adopt topic modify retrospective method result report period begin january present topic prior period amount adjust continue report accordance historical accounting topic elect package practical expedient permit transition guidance topic allow carry forward historical lease classification retain initial direct cost lease exist prior adoption standard reassess contract enter prior adoption lease elect account lease nonlease component lease agreement single lease component determine lease asset liability addition elect recognize rightofuse asset liability lease lease term year adoption topic record million rightofuse asset longterm asset million operating lease liability classify primarily longterm obligation consolidate balance sheet january adoption material impact consolidate statement operation consolidated statement cash flow note lease additional information recently issue accounting pronouncement adopt june fasb issue accounting standard update financial instrumentscredit loss measurement credit loss financial instrument asu asu require measurement recognition expect credit loss financial asset april fasb issue clarification asu asu codification improvement topic financial instrumentscredit loss topic derivative hedge topic financial instrument guidance effective begin quarter adopt modify retrospective approach certain exception expect adoption standard material impact consolidate financial statement november fasb issue accounting standard update collaborative arrangement topic clarify interaction topic topic asu asu clarifie certain transaction participant collaborative arrangement account asc counterparty customer addition update preclude entity present consideration transaction collaborative arrangement revenue counterparty customer transaction guidance effective begin quarter apply retrospectively january initially adopt topic expect adoption standard material impact consolidate financial statement revenue disaggregation revenue follow table disaggregate product sale product geographic region disaggregate royalty contract revenue geographic region millions year end december year end december year end december europe international total europe international total europe international total product sale atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza ambisome ledipasvirsofosbuvir letairis ranexa sofosbuvirvelpatasvir vemlidy viread vosevi yescarta zydelig total product sale royalty contract revenue total revenue include emtriva tybost represent revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fix dose combination product commercialize janssen sciences ireland uc janssen amount consist sale harvoni authorize generic version harvoni sell separate subsidiary asegua therapeutics llc amount consist sale epclusa authorize generic version epclusa sell separate subsidiary asegua therapeutics llc include cayston hepsera sovaldi information year end december adjusted accordance modify retrospective adoption topic continues report accordance historical accounting topic revenue recognize performance obligation satisfy prior period revenue recognize performance obligation satisfy prior year relate royalty license intellectual property million million year end december respectively change estimate variable consideration relate sale prior year result million increase million decrease revenue year end december respectively contract balances contract asset consist unbilled amount primarily arrangement license intellectual property predominant performance obligation total million million december respectively contract liability material december fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation financial instrument consist primarily cash cash equivalent marketable debt security account receivable foreign currency exchange contract equity security account payable shortterm longterm debt cash cash equivalent marketable debt security certain equity security foreign currency exchange contract report respective fair value consolidate balance sheet equity security readily determinable fair value record measurement alternative cost impairment adjust observable price change orderly transaction identical similar investment issuer shortterm longterm debt report amortize cost consolidate balance sheet remain financial instrument report consolidated balance sheet amount approximate current fair value follow table summarize type asset liability measure fair value recur basis level fair value hierarchy million december december level level level total level level level total asset availableforsale debt security treasury security certificate deposit government agency security nonus government security corporate debt security residential mortgage assetbacke security equity security equity investment galapago money market fund publicly trade equity security defer compensation plan foreign currency derivative contract total liability defer compensation plan foreign currency derivative contract total change fair value equity security result net unrealized gain billion million year end december respectively include income expense net consolidated statement income follow table summarize classification equity investment galapago consolidated balance sheet million december december prepay current asset longterm asset total note collaborative arrangement additional information equity investment galapago follow table summarize classification equity security consolidate balance sheet million december december cash cash equivalent prepay current asset longterm asset total availableforsale debt security classify cash equivalent shortterm marketable security longterm marketable security consolidate balance sheet note availableforsale debt security additional information level input estimate fair value level instrument take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include incomebase marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input substantially foreign currency derivative contract maturity month time horizon counterpartie minimum credit rating equivalent sp global rating moodys investors service inc fitch ratings inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency exchange rate london interbank offer rate libor swap rate input applicable observable commonly quote interval total estimate fair value shortterm longterm debt determine level input base quote market value approximately billion billion december respectively carry value billion billion december respectively level input december asset liability measure level input recur basis contingent consideration liability material fair value acquire iprd asset base probabilityadjuste discount cash flow calculation level fair value measurement input include estimate revenue cost probability technical regulatory success discount rate amount capitalize iprd subject impairment testing completion abandonment associate rd effort fourth quarter recognize impairment charge million associate iprd intangible asset acquire connection acquisition kite pharma inc kite primarily treatment indolent b cell nonhodgkin lymphoma inhl fourth quarter recognize impairment charge million write zero carry value kite program antib cell maturation antigen evaluate treatment multiple myeloma note acquisition note intangible asset additional information policy recognize transfer level classification actual date event change circumstance cause transfer transfer level level level period present availableforsale debt security follow table summarize availableforsale debt security million december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate cost gain loss fair value cost gain loss fair value treasury security certificate deposit government agency security nonus government security corporate debt security residential mortgage asset back security total follow table summarize classification availableforsale debt security consolidate balance sheet million december december cash cash equivalent shortterm marketable security longterm marketable security total follow table summarize availableforsale debt security contractual maturity million december amortize cost fair value year year year year total follow table summarize availableforsale debt security continuous unrealized loss position deem otherthan temporarily impair million month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december corporate debt security december treasury security government agency security nonus government security corporate debt security residential mortgage assetbacked security total hold total position unrealize loss position december respectively base review security believe otherthantemporary impairment december intend sell security believe require sell security recovery amortize cost basis gross realize gain gross realize loss availableforsale debt security material year end december derivative financial instrument operation foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency primarily euro manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrealize gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability entity denominate non functional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity month execute hedge contract quarterly assess hedge effectiveness regression analysis unrealize gain loss aoci reclassify product sale respective hedge transaction affect earning majority gain loss relate hedged forecast transaction report aoci december expect reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding total billion billion december respectively derivative contract allow right offset asset liability present amount gross basis follow table summarize classification fair value derivative instrument consolidate balance sheet million december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative follow table summarize effect foreign currency exchange contract consolidate financial statement millions year end december derivative designate hedge gain loss recognize aoci gain loss reclassify aoci product sale gain recognize income expense net derivative designate hedge gain loss recognize income expense net time time discontinue cash flow hedge result record relate amount income expense net consolidated statement income discontinuance cash flow hedge year present december hold foreign currency exchange contract follow table summarize potential effect offset derivative type financial instrument consolidated balance sheet millions gross amount offset consolidated balance sheet gross amount offset amount assetsliabilitie gross amount consolidated balance present consolidated derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset december derivative asset derivative liability december derivative asset derivative liability acquisition kite pharma inc october acquisition date complete tender offer outstanding common stock kite share cash result kite whollyowne subsidiary acquisition kite help establish foundation improve treatment hematological malignancy solid tumor consideration transfer acquisition million consist million cash outstanding kite common stockholder million cash payment vested equity award holder million warrant holder million represent portion replace stockbase award attributable precombination period addition million exclude consideration transfer represent portion replace stock base award attributable post combination period replacement award expect recognize december unrecognized compensation cost relate replacement award material acquisition kite account business combination acquisition method accounting method require thing asset acquire liability assume recognize fair value acquisition date determination estimate fair value require significant estimate assumption record million reduction goodwill primarily revision defer income taxis result finalization kite preacquisition federal income tax return fair value estimate asset acquire liability assume complete follow table summarize acquisition date fair value asset acquire liability assume consideration transfer millions cash cash equivalent identifiable intangible asset indefinitelive intangible asset iprd outlicense acquire deferred income taxis asset acquire liability assume net total identifiable net asset goodwill total consideration transfer identifiable intangible asset acquire intangible asset primarily related iprd axicabtagene ciloleucel kite program ktex ktec evaluate treatment acute lymphoblastic leukemia estimate aggregate fair value million acquisition date intangible asset relate iprd project consider indefinitelive asset completion abandonment associate rd effort october axicabtagene ciloleucel know commercially yescarta approve fda treatment adult patient relapse refractory diffuse large bcell lymphoma dlbcl line systemic therapy fda approval yescarta million purchase iprd reclassify finitelived intangible asset amortize estimate useful life year straightline method recognize impairment charge million primarily relate axicabtagene ciloleucel treatment inhl recognize impairment charge million write zero carry value kite program note intangible asset additional information additionally acquire outlicense arrangement daiichi sankyo company limit estimate fair value million acquisition date definitelive intangible asset amortize estimate useful life year straightline basis fair value determine estimate probabilityweighte net cash flow attributable outlicense discount present value discount rate represent estimate rate market participant use value intangible asset goodwill million goodwill represent excess consideration transfer fair value asset acquire liability assume represent future economic benefit arise asset acquire individually identify separately recognize goodwill deductible income tax purpose cell design labs inc december acquire issue outstanding stock cell design labs inc privately hold company cell design lab addition approximately share cell design lab obtain acquisition kite acquisition gain new technology platform enhance rd effort cellular therapy cash consideration total million net acquire cash additionally shareholder cell design lab eligible receive contingent development regulatory milestonebase payment million equity interest cell design lab carry value million transaction account asset acquisition result million expense acquire iprd research development expense consolidate statement income inventory follow table summarize inventory millions december raw material work process finish good total report inventory longterm asset total amount report longterm asset primarily consist raw material december year end december record inventory writedown million million relate slow move excess raw material work progress inventory primarily low longterm demand hepatitis c virus hcv product year end december record inventory writedown million million relate excess raw material primarily sustained decrease demand harvoni inventory writedown record year end december material property plant equipment follow table summarize property plant equipment million december land land improvement building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment construction progress subtotal accumulate depreciation amortization total office computer equipment include capitalize software unamortize capitalize software cost consolidate balance sheet million million december respectively capitalize interest construction inprogress include property plant equipment interest capitalize material intangible asset follow table summarize intangible asset net million december december gross foreign currency gross foreign currency carry accumulate translation net carry carry accumulate translation net carrying amortization adjustment amortization adjustment finitelive asset intangible asset sofosbuvir intangible asset axicabtagene ciloleucel dlbcl intangible asset ranexa total finitelive asset indefinitelive asset iprd total intangible asset aggregate amortization expense relate finitelive intangible asset billion billion million year end december respectively primarily include cost good sell consolidated statement income amount capitalize iprd subject impairment testing completion abandonment associate rd effort fourth quarter perform quantitative impairment testing iprd intangible asset probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar profile represent rate market participant use value intangible asset discount cash flow model value intangible asset require use level fair value measurement input include estimate revenue cost probability technical regulatory success comparison assessment low estimate revenue change estimate market opportunity new therapy combination exist therapy approve low estimate revenue reduce fair value iprd intangible asset primarily related axicabtagene ciloleucel treatment inhl carrying value result recognition impairment charge million record research development expense consolidate statement income conclude kite program justify effort base totality clinical datum gather discontinue program result carry value iprd relate kite program write zero record impairment charge million research development expense consolidate statement income iprd impairment charge record follow table summarize estimate future amortization expense associate finitelive intangible asset december millions fiscal year total financial information accrue liability follow table summarize component accrue liability millions december compensation employee benefit income taxis payable accrue payment marketingrelate right acquire japan tobacco inc accrue expense total collaborative arrangement enter collaborative similar arrangement party development commercialization certain product product candidate arrangement involve party active participant operating activity collaboration expose significant risk reward depend commercial success activity arrangement include nonrefundable upfront payment payment option acquire certain right contingent obligation potential development regulatory milestone payment andor salesbase milestone payment royalty payment revenue profitshare arrangement costshare arrangement equity investment galapagos filgotinib collaboration close license collaboration agreement galapago clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor evaluate inflammatory disease indication filgotinib agreement closing upfront license fee payment equity investment galapago subscribe million new ordinary share galapagos price share equity investment net issuance premium million term filgotinib agreement amend exclusive worldwide royaltybearing sublicensable license filgotinib product contain filgotinib december galapagos eligible receive potential future development regulatory milestonebase payment million salesbase milestone payment million plus tiere royalty global net sale range exception certain cocommercialization territory profit shared equally cocommercialization territory uk germany france italy spain belgium netherlands luxembourg share global development cost filgotinib equally period present payment galapagos development cost milestone material termination agreement countrybycountry basis depend circumstance include expiration royalty term cocommercialization territory sale generic product material breach party terminate entire agreement cause follow certain period global collaboration august close option license collaboration agreement collaboration agreement subscription agreement subscription agreement galapago pursuant party enter global collaboration cover galapago current future product portfolio filgotinib closing pay billion license option right million new ordinary share galapagos subscription price share fair value billion include issuance discount million calculate base galapago close stock price date closing subscription agreement remain billion payment record research development expense consolidate statement income pursuant subscription agreement issue warrant confer right subscribe time time number new share issue galapagos sufficient bring number share own issue outstanding share time exercise fourth quarter exercise warrant subscribe million ordinary share galapago share purchase share open market aggregate fair value million bring number share own million approximately share issue outstanding equity investment galapago classify longterm asset consolidate balance sheet subject contractual lockup provision subject year standstill restrict ability acquire voting security galapago exceed issue outstanding voting security galapago agree prior consent galapago dispose equity security galapago prior second anniversary closing subscription agreement dispose equity security galapago fifth anniversary closing subscription agreement disposal issue outstanding voting security galapago subject certain exception termination event designee appoint galapago board director elect fair value option account equity investment galapago investment mark market earning reporting period base market price galapago share believe fair value option well reflect underlying economic investment note fair value measurement additional information collaboration agreement exclusive license development commercialization glpg phase candidate idiopathic pulmonary fibrosis territory option participate development commercialization glpg phase b candidate osteoarthritis galapago current future clinical program enter clinical development year collaboration subject extension certain circumstance exercise option program receipt datum package complete qualifying phase study program certain circumstance phase study glpg receive marketing approval united states pay galapagos million tiere royalty describe exercise option glpg program pay million option exercise fee galapago eligible receive million development regulatory commercial milestone tiere royalty describe respect program galapagos current future pipeline exercise option program pay million option exercise fee program addition galapago receive tiere royalty range net sale territory galapago product optione include glpg glpg exercise option program party share equally development cost mutually agree commercialization cost incur subsequent exercise option galapago retain exclusive commercialization right optione program european union uk iceland norway lichtenstein switzerland exclusive commercialization right country globally glpg acquire right terminate collaboration entirety programbyprogram countrybycountry basis advance notice follow customary termination event janssen compleraeviplera odefsey enter license collaboration agreement janssen sciences ireland uc janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell brand complera united states eviplera european union agreement amend expand collaboration include product contain janssen rilpivirine emtricitabine tenofovir alafenamide odefsey amend agreement janssen grant exclusive license compleraeviplera odefsey worldwide retain right distribute combination product certain country outside united states party restrict combine drug drug product similar component compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country sell party financial provision amendment sell party set price combine product party share revenue base ratio net selling price party component subject certain restriction adjustment retain specify percentage janssen share revenue include major market sale product include product sale janssen share revenue include cost good sell consolidated statement income cost good sell relate janssen share million million million year end december respectively termination agreement product country basis depend circumstance include withdrawal product market material breach party expiry revenue share payment term terminate agreement cause respect country sell product case janssen right sell party country product launch market few year symtuza amend license collaboration agreement janssen develop commercialize fixeddose combination janssen darunavir cobicistat emtricitabine tenofovir alafenamide combination approve united states european union july september respectively sell brand symtuza term amendment grant janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property relate cobicistat emtricitabine tenofovir alafenamide gilead compound exclusive supplier gilead compound party restrict combine drug drug product similar component symtuza janssen set price symtuza party share revenue base ratio net selling price party component subject certain restriction adjustment intellectual property license supply obligation relate gilead compound account single performance obligation license deem predominant item revenue share relate recognize share symtuza revenue period correspond sale symtuza janssen occur record share symtuza revenue product sale consolidate statement income primarily supply gilead compound janssen symtuza note revenue revenue recognize period present termination agreement product country basis depend circumstance include withdrawal product market material breach party expiry revenue share payment term janssen terminate agreement cause countrybycountry basis case gilead right sell party countryie product launch market few year janssen terminate entire agreement cause japan tobacco japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right pay royalty base product sale japan agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort pay royalty japan tobacco base product sale japan tobacco market distribute certain product hiv portfolio japan pay royalty base product sale receive approval stribild genvoya elvitegravircontaine product respectively sale product include product sale royalty japan tobacco base product sale include cost good sell royalty japan tobacco base product sale japan include royalty contract revenue consolidate statement income royalty expense recognize million million million year end december respectively royalty income recognize material period present effective december enter agreement japan tobacco acquire right market distribute certain product hiv portfolio japan expand right develop commercialize elvitegravir include japan responsible marketing product january term agreement pay japan tobacco million cash million pay upfront payment remain million pay recognize intangible asset million reflect estimate fair value marketingrelate right acquire japan tobacco remain million record prepay current asset consolidate balance sheet intangible asset amortize year represent period majority benefit expect derive applicable product hiv portfolio amortization expense classify selling expense record sell general administrative expense consolidate statement income termination agreement product country basis depend circumstance include material breach party expiry royalty payment term terminate entire agreement cause gadeta july enter collaboration arrangement gadeta privatelyheld company base utrecht netherlands develop gamma delta cell receptor therapie cancer financial term provide rd funding collaboration gadeta eligible receive future payment achievement certain regulatory milestone addition upfront purchase equity gadeta gadeta shareholder acquire additional equity gadeta achievement certain rd milestone exclusive option acquire remain equity gadeta million adjust closing cash transaction expense close indebtedness option exercisable discretion gadeta vie primary beneficiary power direct activity gadeta significantly impact economic performance result financial term describe initial consolidation gadeta record asset million primarily intangible asset relate iprd million noncontrolling interest consolidate balance sheet gadeta meet definition business define asc business combination result goodwill recognize bristolmyers squibb company north america collaboration arrangement bristolmyers squibb company bms develop commercialize single tablet regimen contain truvada bmss sustiva efavirenz united states canada combination sell brand atripla bms structure collaboration joint venture operate limited liability company consolidate december terminate bmss participation collaboration follow launch generic version sustiva sole owner joint venture bms permit commercialize atripla united states canada entitle receive certain fee base net sale atripla decline annual scale bms supply sustiva cost plus markup threeyear period terminate supply agreement notice period bms notify voluntary termination supply agreement year end december record million million respectively fee expense cost good sell consolidated statement income europe gilead sciences ireland uc whollyowne subsidiary bms collaboration agreement set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bmss estimate net selling price efavirenz european territory party form limited liability company hold marketing authorization atripla european territory start limited number activity jointly manage party long coordinate detail promotional activity european territory responsible manufacturing product distribution inventory management warehouse primary responsibility regulatory activity local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz december efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidate balance sheet september bm elect voluntarily terminate agreement effective march post termination bms permit commercialize atripla european territory entitle receive certain fee base net sale atripla decline annual scale threeyear period follow effective date termination collaboration arrangement individually significant enter collaborative similar arrangement include equity investment licensing arrangement consider individually material cash outflow relate arrangement total million million year end december respectively record upfront collaboration licensing expense relate arrangement million million year end december respectively research development expense consolidate statement income remain amount record current longterm asset consolidate balance sheet material cash payment relate individually insignificant collaboration arrangement enter financial term arrangement require payment achievement developmental regulatory commercial milestone significant future milestone payment reflect consolidated statement income correspond event probable addition require pay significant royalty future sale product relate arrangement commercialize payment amount contingent occurrence future event high degree uncertainty occurrence debt credit facility follow table summarize carry borrowing financing arrangement million december type borrowing issue date date interest rate senior unsecured september march month libor senior unsecured march april senior unsecured september september senior unsecured september september month libor senior unsecured november february senior unsecured september september senior unsecured march april senior unsecured december december senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march total debt net current portion total longterm debt net senior unsecured note enter borrowing connection acquisition kite issue billion aggregate principal senior unsecured note million principal balance repay maturity remain billion repay maturity collectively refer senior unsecured note issue september note september notes march november notes march december note senior note repay maturity million billion principal balance relate note note respectively february repay maturity million principal balance relate note senior note redeem option redemption price equal great principal note redeem ii sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus premium define indenture senior note mature feature exercisable option redeem note par month immediately precede maturity case accrue unpaid interest require redeem date redemption event occurrence change control downgrade rate senior note investment grade moodys investors service inc sp global rating holder require purchase portion note price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase require comply certain covenant senior note december violation covenant interest expense senior note relate contractual coupon rate amortization debt discount issuance cost billion billion billion respectively credit facility connection acquisition kite borrow billion term loan credit facility billion repay remain billion repay term loan credit facility agreement terminate enter billion fiveyear revolve credit facility agreement mature fiveyear revolve credit agreement revolve credit facility work capital requirement general corporate purpose include limitation acquisition december amount outstanding fiveyear revolve credit agreement fiveyear revolve credit agreement contain customary representation warranty affirmative negative covenant event default december violation covenant loan fiveyear revolve credit agreement bear interest eurodollar rate plus applicable percentage ii base rate plus applicable percentage define fiveyear revolve credit agreement terminate reduce commitment prepay loan fiveyear revolve credit agreement time premium penalty contractual maturity finance obligation december aggregate future principal maturity finance obligation year base contractual date follow millions contractual maturity lease operating lease consist primarily property equipment administrative manufacturing rd activity determine arrangement contain lease inception rightofuse asset lease liability recognize commencement date base present value lease payment lease term noncancelable period state contract adjust option extend terminate reasonably certain exercise option lease include option extend term year include option terminate lease year lease commencement date rightofuse asset adjust prepay lease payment lease incentive initial direct cost incur december material finance lease operating lease provide implicit interest rate generally utilize collateralized incremental borrowing rate apply portfolio approach relevant base information available commencement date determine lease liability operate lease expense minimum lease payment recognize straightline basis lease term operating lease expense include variable cost shortterm lease million year end december operating lease expense prior lease standard million million year end december respectively follow table summarize balance sheet information relate operating lease december millions weight average amount classification rightofuse asset net longterm asset lease liability current accrue liability lease liability noncurrent longterm obligation weight average remain lease term year weight average discount rate follow table summarize supplemental information relate operating lease million year end december cash pay amount include measurement lease liability rightofuse asset obtain exchange lease liability follow table summarize maturity analysis operating lease liability show aggregate lease payment december millions fiscal year total undiscounted lease payment imputed interest total discount lease payment follow table summarize aggregate undiscounted noncancelable future minimum lease payment operating lease prior lease standard december millions fiscal year total minimum lease payment commitment contingency legal proceeding party legal action significant describe recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine loss reasonably possible loss range loss estimate disclose possible loss note possible determine outcome matter reasonably estimate maximum potential exposure range possible loss material accrual matter describe consolidated balance sheet december litigation relate sofosbuvir acquire pharmasset inc pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hcv receive approval fda sofosbuvir know commercially sovaldi sofosbuvir include market hcv product receive number litigation claim sofosbuvir carefully consider claim prior follow acquisition believe merit predict ultimate outcome claim range loss aware patent patent application own party future allege party cover use hcv product party obtain valid enforceable patent successfully prove infringement patent hcv product require pay significant monetary damage predict ultimate outcome intellectual property claim relate hcv product spend continue spend significant resource defend claim litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii idenix udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent patent prevail phase litigation concern patent supreme court deny idenixs petition certiorari idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent patent court transfer massachusetts litigation district court district delaware prior trial idenix commit covenant sue respect claim arise patent relate sofosbuvir withdraw patent trial jury trial hold patent jury find willfully infringe assert claim patent award idenix billion past damage judge invalidated idenixs patent vacate jurys award billion past damage idenix appeal decision court appeal federal circuit cafc october cafc issue opinion affirm trial court decision patent invalid idenix petitioned rehear cafc en banc seek review supreme court litigation university minnesota university minnesota university obtain patent patent purport broadly cover nucleosides antiviral anticancer activity university file lawsuit district court district minnesota allege commercialization sofosbuvircontaine product infringe patent believe patent invalid infringe continue commercialization sofosbuvir court grant motion transfer case california file petition inter parte review patent trademark office uspto patent trial appeal board ptab allege assert claim invalid anticipation obviousness district court northern district california stay litigation ptab rule petition inter part review litigation relate axicabtagene ciloleucel patent patent application protect axicabtagene ciloleucel chimeric dna segment party obtain right patent allegedly prevent attempt prevent commercialize axicabtagene ciloleucel require obtain license order commercialize axicabtagene ciloleucel october juno therapeutics inc sloan kettere cancer center collectively juno file lawsuit district court central district california allege commercialization axicabtagene ciloleucel sell commercially yescarta infringe patent patent jury trial hold patent december jury find asserted claim patent valid willfully infringe assert claim patent jury award juno damage amount million upfront payment run royalty october date jurys verdict party file posttrial motion january file briefing quarter expect judge rule matter later district court issue ruling enter judgment case appeal cafc predict certainty ultimate outcome litigation believe jurys verdict error believe error court respect certain ruling trial assess accrue liability litigation consolidate financial statement consider factor include legal factual circumstance case jurys verdict district court pre posttrial order current status proceeding applicable law view legal counsel likelihood jurys verdict upheld appeal result review determined accordance applicable accounting standard probable incur material loss result litigation jurys verdict upheld appeal loss zero jurys verdict upheld entirety appeal estimate upper end range possible loss december approximately billion consist million upfront payment determined jury ii approximately million represent estimate royalty adjust revenue yescarta october december iii enhance damage request juno time sum ii result jurys find willfulness sum exclude cost pre judgment interest supplemental damage consist royalty sale yescarta december date judgment subject royalty jurys verdict prospective royalty propose juno enhancement postjudgment sale yescarta subject prospective royalty estimate payable adjusted yescarta revenue judgment expiry patent august expect judge rule prospective royalty enhance damage course decide posttrial motion court determination prospective royalty enhance damage appeal litigation relate bictegravir viiv healthcare company viiv file lawsuit district court delaware allege commercialization bictegravir sell commercially combination tenofovir alafenamide emtricitabine biktarvy infringe viiv patent patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claim patent extent viivs patent claim interpret cover bictegravir believe claims invalid court set trial date september lawsuit viiv file lawsuit federal court canada allege activity relate bictegravir compound infringe viiv canadian patent patent issue shionogi co ltd viiv patent compound patent covering viivs dolutegravir believe bictegravir infringe claim patent january court hold summary trial assess viivs infringement allegation court decision expect march november december viiv file lawsuit france germany ireland uk assert relevant national designation european patent australia assert australian patent japan assert japanese patent korea assert korean patent nos patent relate molecule viiv claim act integrase inhibitor believe bictegravir infringe claim viivs patent jurisdiction extent claim viivs patent interpret cover bictegravir believe claim invalid predict ultimate outcome intellectual property claim relate bictegravir litigation relate preexposure prophylaxis august file petition request inter parte review patent nos patent patent collectively hhs patent ptab hhs patent assign department health human service purport claim process protect primate host infection immunodeficiency retrovirus administer combination emtricitabine tenofovir tdf prior exposure host immunodeficiency retrovirus process commonly know preexposure prophylaxis prep november department justice file lawsuit district court delaware allege sale truvada descovy use prep infringe hhs patent february ptab decline institute petition inter part review hhs patent predict certainty ultimate outcome litigation believe truvada descovy infringe hhs patent hhs patent invalid prior art description truvada use prep postexposure prophylaxis physician patient claim method year center disease control prevention file application patent litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product early patent expiration significant negative effect revenue result operation seek approval generic version product nce status generic company submit anda fda year brand product approval start december receive letter lupin ltd apotex inc shilpa medicare ltd sunshine lake pharma co ltd laurus labs natco pharma ltd cipla ltd collectively generic manufacturer indicate submit andas fda request permission market manufacture generic version certain tenofovir alafenamide tafcontaine product generic manufacturer seek market generic version odefsey descovy vemlidy generic manufacturer challenge validity patent list orange book associate taf challenge validity orange bookliste patent associate taf evaluate letter intend enforce defend intellectual property european patent claim party file opposition european patent office epo request revocation grant european patent cover sofosbuvir expire epo uphold validity certain claim sofosbuvir patent appeal decision seek restore original claim original oppose party appeal request revocation appeal hearing schedule july party file opposition epo request revocation grant european patent relate sofosbuvir expire epo conduct oral hearing opposition uphold claim original oppose party appeal request revocation party file opposition epo request revocation grant european patent cover taf expire epo upheld validity claim taf patent party appeal decision party file opposition epo request revocation grant european patent relate taf hemifumarate expire epo upheld validity claim taf hemifumarate patent party appeal decision party file opposition epo request revocation grant european patent cover cobicistat expire epo upheld validity claim cobicistat patent party appeal decision appeal process year epo opposition proceeding confident strength patent predict ultimate outcome opposition unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir taf taf hemifumarate cobicistat european union substantially shorten eliminate entirely patent revoke european patent grant covering compound exclusivity base entirely regulatory exclusivity grant european medicine agency lose patent protection compound revenue result operation negatively impact year include succeed year exclusivity lose government investigation relate litigation receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperate government inquiry department justice inform follow investigation decline intervene false claim act lawsuit file employee employee serve amend complaint district court northern district california issue order grant entirety prejudice motion dismiss amend complaint plaintiff file second amend complaint district court issue order grant motion dismiss second amend complaint plaintiff file notice appeal court appeal ninth circuit ninth circuit ninth circuit grant motion stay case pende appeal supreme court file petition writ certiorari supreme court solicitor general submit brief united states supreme court state intention file motion dismiss federal false claim act january supreme court deny petition case remand district court march department justice file motion dismiss second amend complaint district court grant department justice motion dismiss november dismiss relator federal false claim act claim receive subpoena attorney office district massachusetts request document relate support c organization provide financial assistance patient document concern provision financial assistance patient hcv product cooperate inquiry receive subpoena attorney office district massachusetts request document relate copay coupon program medicaid price report methodology cooperate inquiry receive voluntary request information attorney office eastern district pennsylvania request information relate reimbursement support offering clinical education program interaction specialty pharmacy sovaldi harvoni receive voluntary request information relate speaker program advisory board hcv hepatitis b virus product cooperate voluntary request october department justice inform follow investigation decline intervene false claim act lawsuit relate hepatitis b speaker program advisory board bring plaintiff district court eastern district pennsylvania notwithstanding government declination plaintiff continue pursue lawsuit serve second amend complaint november predict ultimate outcome lawsuit believe action merit intend vigorously defend receive subpoena california department insurance alameda county district attorney office request document relate marketing activity reimbursement support offering clinical education program interaction specialty pharmacy harvoni sovaldi cooperate inquiry receive subpoena attorney office southern district new york request document relate promotional speaker program hiv cooperate inquiry product liability name defendant class action lawsuit product liability lawsuit relate viread truvada atripla complera stribild plaintiff allege viread truvada atripla complera andor stribild cause suffer kidney andor bone injury lawsuit pende state federal court california delaware florida involve thousand plaintiff plaintiff case seek damage relief ground allege personal injury economic loss intend vigorously defend action believe case merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage antitrust consumer protection japan tobacco bms johnson johnson inc name defendant class action lawsuit file related drug treat hiv include drug combination antiretroviral therapy plaintiff allege defendant engage conduct restrain competition violation federal state antitrust law state consumer protection law lawsuit consolidated action pende district court northern district california seeks bring claim behalf nationwide class endpayor purchaser similar lawsuit recently file district court southern district florida consolidated plaintiff seek damage permanent injunctive relief relief intend vigorously defend action believe action merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage subject permanent injunctive relief matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient api certain inventory relate item december commitment year approximately million million million million million amount relate api represent minimum purchase commitment actual payment purchase api certain inventory relate item million billion billion january amend api contract increase firm purchase commitment approximately million stockholder equity stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction december remain authorize repurchase program billion follow table summarize stock repurchase program million share amount year end december share repurchase retire average price share addition repurchase program repurchase share common stock withhold employee restrict stock award satisfy applicable tax withholding obligation immaterial exclude table use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate additional paidin capital apic base estimate average sale price issue share excess amount charge retain earning follow table summarize reduction common stock apic charge retain earning result stock repurchase millions year end december reduction common stock apic charge retain earning quarter board director authorize new billion stock repurchase program program commence completion program purchase program open market privately negotiate transaction dividend follow table summarize cash dividend declare common stock million share amount dividend share dividend share quarter second quarter quarter fourth quarter total restrict stock performance share award unit dividend equivalent right entitle holder dividend equivalent pay vest share underlie unit february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march future dividend subject declaration board director prefer stock million share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december accumulate comprehensive income follow table summarize change aoci component net tax million unrealize gain loss unrealize gain foreign currency availableforsale loss translation debt security cash flow hedge total balance december reclassification retain earning result adoption new accounting standard balance january net unrealized loss gain reclassification net income net current period comprehensive loss income balance december net unrealize gain reclassification net income net current period comprehensive income loss balance december amount reclassify net income gain loss cash flow hedge record product sale consolidate statement income note derivative financial instrument additional information amount reclassify net income gain loss availableforsale debt security record income expense net consolidated statement income income tax impact allocate component comprehensive income material period present employee benefit provide sharebased compensation form type equitybase award include restrict stock unit rsus performance share award unit psus stock option compensation expense recognize consolidated statement income base estimate fair value award grant date estimate fair value rsus base closing price common stock psus estimate fair value base monte carlo valuation methodology stock price date grant stock option award estimate fair value base blackschole option valuation model equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan amend plan plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance share award employee director consultant plan authorize issuance total million share common stock december total million share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option stock option grant january nonqualified stock option employee stock option generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share follow table summarize activity relate information stock option plan option grant present table exercise price fair value underlie common stock grant date weight weightedaverage aggregate average remain intrinsic share exercise price contractual term value million dollar year million outstanding december grant forfeit expired exercise outstanding december exercisable december expect vest net estimate forfeiture december aggregate intrinsic value represent value close stock price trading day year excess weightedaverage exercise price multiply number option outstanding exercisable total intrinsic value option exercise million million million weightedaverage grant date fair value stock option grant share share share weightedaverage grant date fair value stock option grant high replacement award grant connection acquisition kite cell design labs december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year restrict stock performance share award grant timebase rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus sharebase awards entitle holder receive freely tradable share common stock vest rsus generally vest year date grant fair value rsu equal closing price common stock grant date grant psus vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target actual number common share ultimately issue calculated multiplying number psus payout percentage range award generally vest committee subcommittee board determine specify market performance goal achieve fair value psu estimate date grant performance objective define grant depend term award fair value date grant determine base monte carlo valuation methodology closing stock price date grant addition grant psus certain employee plan vest award subject achievement specify individual performance goal typically year period fair value award equal closing price common stock grant date follow table summarize rsu psu activity relate information million share amount rsus psus weighted weight average average grant date fair value grant date fair value share share share share outstanding december grant vest forfeited outstanding december weightedaverage grantdate fair value share exclude share relate grant currently grant date performance objective define weightedaverage grant date fair value rsus grant share share share weightedaverage grant date fair value psus grant share share share total grant date fair value vest rsus psus million million million total fair value respective vest date million million million december million unrecognized compensation cost relate unvested rsus psus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan international employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date espp offer sixmonth lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period espp purchase settle common stock espps previously authorize available pool share million share issue espp million total million share common stock authorize issuance espp million share available issuance espp december stockbase compensation follow table summarize total stockbased compensation expense include consolidated statement income million year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax income tax effect year end december include million income tax expense follow court appeal decision altera corp v commissioner require related party intercompany cost sharing arrangement share expense relate stockbased compensation income taxis additional information stockbase compensation recognize expense requisite service period consolidate statement income straightline expense attribution approach reduce estimate forfeiture estimate forfeiture base historical experience requisite service period shorter vest period employee retirement eligible valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout defer compensation maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead science k plan certain foreign subsidiary maintain define benefit plan require local regulatory requirement total matching contribution expense gilead science k plan define benefit plan million million million maintain deferred compensation plan director key employee defer compensation amount defer participant deposit rabbi trust total asset liability associate defer compensation plan million december million december net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock dilutive security outstanding period potentially dilutive share common stock result assume exercise outstanding stock option equivalent determine treasury stock method potential share common stock exclude computation dilute net income share attributable gilead common shareholder effect antidilutive million million million respectively follow table show calculation basic diluted net income share attributable gilead common stockholder million share amount year end december net income attributable gilead share share calculation basic dilutive effect stock option equivalent share share calculation dilute net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder dilute segment information operating segment primarily focus discovery development commercialization innovative medicine area unmet medical need chief executive officer ceo chief operating decisionmaker manage allocate resource operation company entitywide basis manage allocate resource entitywide basis enable ceo assess overall level resource available well deploy resource function rd project base unmet medical need necessary reallocate resource internal rd portfolio external opportunity good support longterm growth business note revenue summary disaggregate revenue product geographic region revenue major customer follow table summarize revenue customer individually account total revenue percentage total revenue year end december amerisourcebergen corp cardinal health inc mckesson corp longlived assets net book value property plant equipment office computer equipment united states billion december billion december billion december corresponding international location million december million december million december individual international location account total balance income taxis income provision income taxis consist follow millions year end december domestic foreign income provision income taxis provision income taxis consist follow millions year end december federal current deferred state current defer foreign current defer provision income taxis provision income taxis include billion defer tax benefit relate intangible asset transfer foreign subsidiary ireland united states fourth quarter complete intraentity asset transfer certain intangible asset foreign subsidiary ireland transaction result stepup irish taxdeductible basis transfer asset accordingly create temporary difference tax basis exceed book basis intangible asset result recognize defer tax asset billion consolidated financial statement tax deduction amortization asset recognize future amortization deduct tax purpose carry forward indefinitely irish tax law expect able realize defer tax asset result intraentity asset transfer impact intangible asset transfer foreign subsidiary united states material provision income taxis include million defer tax charge relate transfer acquire intangible asset foreign subsidiary united states transaction result stepup taxdeductible basis result recognize defer tax liability million temporary difference book basis exceed tax basis acquire intangible asset provision income taxis include billion provisional charge income tax expense relate tax reform enact december tax reform significant change internal revenue code amend include limited corporate tax rate decrease effective tax year begin december repatriation tax deem repatriate earning foreign subsidiary implementation modify territorial tax system effect subject earning foreign subsidiary taxation gilti elect account tax gilti period cost method reconciliation federal statutory tax rate apply income taxis effective tax rate summarize follow year end december federal statutory rate state taxis net federal benefit foreign earning different rate research credit tax foreign earning defer tax intraentity transfer intangible asset transition tax defer tax revaluation settlement tax examination effective tax rate defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow million december defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible excess tax basis book basis intangible asset upfront milestone payment research credit carryforward net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability property plant equipment excess book basis tax basis intangible asset total defer tax liability net defer tax asset liability valuation allowance million million december respectively decrease valuation allowance primarily relate reduction net operating loss carryforward asset recognition framework correspond valuation allowance respect certain foreign jurisdiction december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately billion million respectively state net operating loss start expire utilize state tax credit carryforward carry forward indefinitely utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return unite states foreign jurisdiction federal income tax purpose statute limitation open onwards onwards california income tax purpose certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year income tax return subject audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position total unrecognized tax benefit billion billion december recognize reduce effective tax rate period recognition interest penalty relate unrecognized tax benefit include provision income taxis consolidate statement income million year end december interest penalty relate unrecognized tax benefit year end december respectively material accrue interest penalty relate unrecognized tax benefit million million december respectively december believe reasonably possible unrecognized tax benefit materially change month potential resolution tax authority estimate range reasonably possible change determine time june ninth circuit court appeal ninth circuit issue opinion altera corp v commissioner reverse prior decision united states tax court require related party intercompany costshare arrangement share expense relate stockbased compensation july taxpayer request rehear ninth circuit request deny november result record cumulative income tax expense million fourth quarter february taxpayer request hear supreme court united states final outcome case uncertain record income tax expense fourth quarter base ninth circuit denial follow rollforward total gross unrecognized tax benefit million year end december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period select quarterly financial information unaudite million share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale net income loss net income loss attributable gilead net income loss share attributable gilead common stockholder basic net income loss share attributable gilead common stockholder dilute total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder dilute amount quarter include upfront collaboration licensing expense billion basic diluted share relate collaboration galapago note collaborative arrangement additional detail amount fourth quarter include billion favorable tax effect relate intraentity intangible asset transfer million pretax net gain equity security partially offset million pretax impairment charge relate inprocess research development iprd intangible asset acquire connection acquisition kite pretax writedown million slow move excess raw material work process inventory note fair value measurement note inventory note intangible asset note income taxis additional detail amount fourth quarter include net favorable impact basic share diluted share factor note footnote amount fourth quarter include million pretax impairment charge relate iprd intangible asset acquire connection acquisition kite million noncash tax charge relate transfer acquire intangible asset foreign subsidiary united states pretax writedown million excess raw material primarily sustained decrease demand harvoni note inventory note intangible asset note income taxis additional detail amount fourth quarter include unfavorable impact basic share diluted share factor note footnote gilead sciences inc schedule ii valuation qualifying account million balance begin additionscharged balance end period expense deduction period year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset allowance doubtful account cash discount chargeback item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule ae securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify security exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include item annual report issue report internal control financial reporting december report audit internal control financial reporting appear c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting report independent register accounting firm stockholder board director gilead sciences inc opinion internal control financial reporting audit gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework coso criterion opinion gilead sciences inc company maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states pcaob consolidate balance sheet company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note financial statement schedule list index item report date february express unqualified opinion thereon basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate ernst young llp san jose california february item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading gilead board director nominees board structure executive officer applicable delinquent section report write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance intend disclose future amendment certain provision code ethic waivers code ethic grant executive officer director website business day follow date amendment waiver item executive compensation information require item incorporate reference section proxy statement heading executive compensation committee board director compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference item annual report head equity compensation plan information section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading gilead board director board process item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service iv item